Indonesia: South-South Trade Promotion Programme

SOUTH-SOUTH TRADE PROMOTION PROGRAMME
INDONESIA
SUPPLY AND DEMAND SURVEY ON
PHARMACEUTICALS AND NATURAL PRODUCTS
December 2007
Indonesian Chamber of Commerce
Industry (KADIN)
Jakarta 12950, Indonesia
Tel. (6221) 527 44 84-5
Fax: (6221) 527 4331-2
E-mail: hariadi@kadin-indonesia.or.id
and
Supply and demand survey on pharmaceuticals and natural products Indonesia
The designations employed and the presentation of the material in this document do not imply the
expression of any opinion whatsoever on the part of the International Trade Centre (ITC)
concerning the legal status of any country, territory, city or area or of its authorities, or
concerning the delimitation of its frontiers or boundaries.
While every effort has been made to verify the information contained in this document, ITC
cannot accept any responsibility for any errors that it may contain.
This report has not been formally edited by the International Trade Centre (ITC)
- ii -
Table of contents
I.
INTRODUCTION .........................................................................................................................5
A.
B.
C.
OBJECTIVES AND SCOPE OF THE REPORT .......................................................................................5

METHODOLOGY ............................................................................................................................8
SIGNIFICANCE ...............................................................................................................................9
II.
SUMMARY OF CONCLUSIONS AND RECOMMENDATIONS...................................10
III.
MAIN REPORT.......................................................................................................................15
A.
B.
C.
D.
E.
F.
G.
H.
I.
J.
K.
L.
M.
N.
O.
IV.
V.
INDUSTRY OVERVIEW..................................................................................................................15
PRODUCTION CAPACITY ..............................................................................................................15
MARKET CHARACTERISTICS ........................................................................................................19
EXTERNAL TRADE ......................................................................................................................24
STANDARDS AND TECHNICAL REGULATIONS ...............................................................................32
TRADE AND INDUSTRY POLICY ENVIRONMENT ............................................................................33
EXPORT POLICIES AND INCENTIVES .............................................................................................41
IMPORT PRACTICES .....................................................................................................................41
DISTRIBUTION SYSTEM ...............................................................................................................43
PHARMACEUTICAL SALES PROMOTION AND PRICING...................................................................47
MARITIME TRANSPORT SERVICES ................................................................................................48
PACKAGING ................................................................................................................................49
EXPORT CREDIT AND FINANCE ....................................................................................................53
TRADE PROMOTION .....................................................................................................................56
CONCLUSIONS AND RECOMMENDATIONS ....................................................................................58
USEFUL ADDRESSES ...........................................................................................................64
REFERENCES.............................................................................................................................68
- iii -
NOTES
The following abbreviations are used:
ACCSQ
ASEAN Consultative Committee for Standards and Quality
ACTD
Common Technical Dossier
ACTR
Agreement on Common Technical Requirements
APEC
Asia Pacific Economic Cooperation
ASEAN
Association of Southeast Asian Nations
ATL
Accelerated Tariff Liberalization
CEPT
Common Effective Preferential Tarriff
CIF
Cost, Insurance and Freight
EDL
Essential Drug List
ECFIN
Economic and Finance
FOB
Free on Board
GMP
Good Manufacturing Practices
ITC
International Trade Centre
MRA
Mutual Recognition Agreement
NEDL
National Essential Drug List
OTCs
Over-The-Counter Drugs
R&D
Research and Development
TRIPS
Agreement on Trade-Related Aspects of Intellectual Property Rights
VAT
Value Added Tax
WHO
World Health Organization
WTO
World Trade Organization
- iv -
I.
A.
INTRODUCTION
Objectives and scope of the report
This report was prepared based on the terms of reference prepared by the International Trade Centre
(ITC) initially in 2005 and subsequently updated to 2007. The objectives of this survey are as follows:
To outline the current market size and be able to project the future potential
To understand the complexities of the market structure and its characteristics viz. the distribution
channels employed and their relative importance, layers of middlemen, etc.
To highlight the Import Policy and procedures, i.e. rules and regulations, duties, customs
valuation, and practices, etc.
To identify the major impediments affecting imports, and suggest remedial action
To identify the major impediments affecting exports, and suggest remedial action
Indicating possibilities for augmenting supplies and new investment opportunities
Determining technical assistance requirements in the areas of product development, packaging,

market promotion, joint export marketing, export financing, costing and pricing, training in export
marketing, etc.
This report consists of nine parts and appendices. The first part of the report deals with the objective,
methodology and sources of information and product description. The second part concerns the
domestic industry of pharmaceutical products and materials. The third part discusses the import aspect
and the fourth part deals with export aspect.
The fifth part of the report concerns the market structure and volume as well as key players. The sixth
part focuses on demand analysis including issue on health condition, health system, per capita
consumption of pharmaceuticals and others. Part seven covers the distribution system of
pharmaceuticals while Part 8 covers the government regulation related with investment, trading and
import of pharmaceuticals.
Following are the 21 categories of medicines (covering 128 groups) that are manufactured in
Indonesia and a subject of this survey:
Category
Alimentary System
Group
a. Antacid, Antiulecerants
b. GIT regulators, Antiflatulents & Anti inflammatories
c. Antispasmodies
d. antidiarrheals
e. Laxatives, Purgatives
f. Disgestives
g. Ahollagues, Chollelitholtytics & Hepatic Protector
-5-
Category
Cardiovascular
&
Hematopoleitic
System
Respiratory System
Neuro Muscular System
Hormons
Contrceptive Agents
Group
a. Cardiac Drugs
b. Anti anginal Drugs
c. ACE-Inhibitors/Other Antihypertensives
d.Beta Blockers
e. Calciumantogonists
f.Diureties
g. Antidiureties
h. Periperal Vasodilator & CerebralActivators
i. Vasconstrictors
j. Migrain Drugs
Haemostatics
m. Anticoagulants, antithrombotics & Fibrinolytics
n. Haemorrheologicals
o. Haemotopoietic Agents
p. Other Cardiovascular Drugs
a. Respiratory Stimulants
b. Antiasthmatic Preparations
c. Cough & Cold Remedies
d. Decongestant & Other Nastal Preparation
e. Other Drugs Acting on Respiratory System
a. Anti inflammatory Enzymes
b. Anlgesic & Antipyretics
c. Antirheumatic, anti inflammatory Analgesic
d. Gout Preparation
e. Minor Tranquilliesers
f. Major Tranquilliesers
g. Hypnotics & Sedaties
h. Anticonvulsants
i. Antidepressants
j. CNS Stimulants
k. Nootropics & Neurotronics
l. Antiemetics & Antivertigo Drugs
m. Neurodegeneratives Disease drugs
n. Antiparkinsonism Preparations
o. Neumucular Disoreder
p. Muscle Relaxants
a. Androgens & related Synthetics Drugs
b. Oestrogens & Progesterons & related Synthetics
Drugs
c. Combined Sex Hormons
d. Corticosteroid Hormons
e. Tropics Hormones & Related Synthetics Drugs
f. Anabolic Agents
g. Other Hormone Related Drugs
a. Depot Contraceptive
b. Oral Contraceptive
c. Other Contraceptive
-6-
Category
Antibiotics
Other Chemotherapeutics
Genito-Urinary System
Metabolism
Vitamins & Minerals
Nutritions
Eye
Group
a. Aminoglycosides
b. Cephalosporints
c. Chlorampheniols
d. Macrolides
e. Penicilins
f. Quinolones
g. tetracyclines
h. Antifungals
i. Antibaeterials Combinations
j.Other Antibiotics
a. Antitubercolous Agents
b. Sulphonamides
c. Antiamoebics
d. Anthelmintics
e.Antileprotics
f. Antivirals
g. Antineoplastics
h. Antimalarials
i. Filaricides
a. Preparations for vaginal Conditions
b. Urinary Anticeptics
c. drugs Acting on Uterus
d. Other Drugs Acting on Genito-Urinary System
a. insulin
b. Oral Hypoglicaenics Agents
c. Thyroid Preparations
d. Antithyroids
e. Antihyperlipidaenics Agents
f. Other Agents Affecting Methabolism
a. Vitamin A, D, E
b. Vitamin B's/with C
c. Vitamin C
d.Calcium/with Vitamin
e. Multivitamins/with Minerals
f. Vitamin with Hormones/Geriatics Preparations
g. Paediatric Vitamin & Minerals
h. Electrolytes and Minerals
i. Antianaemics/Pre & Post Natal Vitamin
a. Infant/Follow-on Formulae
b. Enteral/Nutrional Products
c. Parenteral Nutrition
d. Tonics
e. Appetite Agents
a. Eye Antiinfecttives & Anticeptics
b. Eye Cortcosteroids
c. Eye Anticeptics with Corticosteroids
d. Mydriatitics drugs
e. Miotics Drugs
f. Glaucoma Preparations
g. Other Eye Preparation
-7-
Category
Ear
Mouth/Throat
Dermatologieals
Anaestethics Local & General

Allergy & Immuns System
Antidotes & Detoxifying Agents

Intravenous & Other Sterie Solutions
Miscellaneous
Source: MIMS Indonesia
Group
a. Ear Antiinfectives & Antiseptics
b. Ear Corticosteroids
c. Ear Antiseptics with Cortiosteroids
d. Other Ear Preparations
a. Mouth/Throat Preparations
a. Antiinfectives
b. Antiinfectives with corticosteroids
c. Topical Corticosteroids
d. Aene treatment Preparations
e. Antiseptics & Disinfectants
g. Fungieides Anti[arasites
h.Psoriasis, Sebborrhea & Lehthosis prep.
i. Topical Antivirals
j. Keratolytives
k. skin protectives
l. Antihistamines/Antipruritics
m. Analgesics & Anti Inflammatories
n. Other dermatoloicals
a. Antihistamines & Antiallergies
b. Vacinnes Antisera & Immunolgcals
c. Immunosuppresents
-
B. Methodology
The survey has been based on findings from primary as well as secondary sources. Primary sources
included one-to-one discussions conducted on-site in Jakarta by KADIN Indonesia (Indonesia
Chamber Of Commerce And Industry), and other independent players in the Indonesian marketplace.
Secondary data such as import and export statistics were collected from BPS (Central Bureau of
Statistics), production figures were collected from the Ministry of Industry and Trade, the business
associations, filed corporate annual reports, the Ministry of Health, World Health Organization, ADB
and others.
The data and information being collected were verified and crosschecked in order to obtain the most
reliable data on the subjects of the study. The study has used a descriptive research as well as market
intelligence approach in their implementation. The data were then processed, tabulated and analyzed
to obtain the industry parameters and trends.
The final report - as presented - was prepared by staff of Indonesia Chamber Of Commerce And
Industry.
-8-
C. Significance
With a population of around 238 million people in 2007, Indonesia has been regarded as a huge
potential market. The prospects of a big market have prompted domestic as well as many foreign
investors to develop industries producing goods and services. The pharmaceutical industry represents
one of these sectors. However, in Indonesia, as in other large developing countries, there has been a
big gap between "potential" and its realization. This applies also to the pharmaceutical industry.
Not all companies operating in Indonesia have profited from the increased consumption of
pharmaceutical products. Many firms are beset with difficulties amid fierce competition; however,
along with the economy, the pharmaceutical industry in general has grown.
-9-
II.
SUMMARY OF CONCLUSIONS AND

RECOMMENDATIONS
The level of healthcare in Indonesia is poor and subject to considerable regional inequalities. Maternal
health is a major problem, and infant mortality is high at 35 in every 1,000 births. Compared with
other low-income countries, Indonesia has fallen behind in terms of investment in infrastructure and
financial resources for health since the economic crisis of 1997-98. Demands on the system are
increasing: demographic trends show an increasing number of people over 60 years of age, and
growing migration to the cities. Average life expectancy has been rising, from 61.2 years in 1990 to
69 years in 2006, resulting in an increase in degenerative diseases.
1.
Private healthcare facilities are expected to expand
The public sectors ability to invest in healthcare provision is limited, and the main obstacle to
achieving adequate health services is low financing of the health sector. Health expenditure in
Indonesia is only around 1.6%-2.6% of GDP. It is far below the 4.5% of GDP average health
expenditure of developing countries.1 Health expenditure of Indonesian people is around US$ 8 to
US$ 18 per person per year, more than 50 % of which is out pocket. Foreign aid to Indonesia average
around US$ 2.3 billion per year, but it only allows to identify obstacles in the absorption of fund and
improve efforts to evently distribute funds. The government has therefore been actively promoting
private healthcare provision, particularly at secondary and tertiary level. The increasing role of the
private sector in healthcare raises questions about access, although private facilities are required to
provide subsidized services to the poor.
Indonesia: Healthcare and pharmaceuticals
2003
68.9
66.5
71.5
38.1
31.4
1.7
3.7
17
0.2
788
Life expectancy average (years)

Life expectancy male (years)
Life expectancy, female (years)
Infant mortality rate (per 1,000 live births)
Healthcare spending (Rp bn)
Healthcare spending (% of GDP)
Healthcare spending (US $ bn)
Healthcare spending (US$ per head)
Physicians (per 1,000 population)
Pharmaceutical sales (US $ m)
2004
69
66.8
71.8
36.8
35.9
1.7
4.2
19
0.2
2,000
2005
67.8
67.5
72.1
35.6
41.5
1.7
5
23
0.2
2,369
2006
67.8
67.4
72.5
35
48.6
1.7
5.8
26
0.2
2,316
2007
68.3
67.69
72.76
32.14
43.1
1.7
10.2
44
0.2
2,417*
Sources: UN Common Database and various sources

* Estimation
Indonesia is coming under mounting international pressure to open its healthcare services to
international competition. There is currently a policy of zero personnel growth in the public sector,
and this will have negative effects on health service delivery.
The country has recently implemented an essential drugs list, resulting in a considerable decline in the
excessive use of antibiotics, multi-drug combinations and injections. State-owned companies are the
main source of pharmaceuticals. Generic drugs are now produced by 4 government and 25 private
companies.
1
Macroeconomics and Health Initiative in Indonesia World Health Organization, April 2006.
- 10 -

The Indonesian pharmaceutical market reached around 23.69 trillion rupiah in 2005 and 23.16 trillion
rupiah in 2006. The market size growth is therefore lower than 2.3%. Ethical drugs decreased by 4.7
% from 14.68 trillion rupiah (2005) to 13.96 trillion rupiah (2006). However, over-the-counter (OTC)
drugs increased by 1% from 9.01 trillion rupiah (2005) to 9.24 trillion rupiah (2006). Generally, the
pharmaceutical market size decerased significantly in 2006 compared to 2005. The decrease ocured
due to the governments campaign to promote the use of generic drugs.
Annual consumption of drugs per head was US$ 9 in 2006, significantly below the US$ 11 recorded
in Thailand and Malaysia. Use of public (and private) health services is low, but a WHO report found
that it was not only the prices of services and drugs that accounted for the low level of use, but also
travel time and cost as well as time lost from other productive activities. Medicines are expensive
relative to average incomes. There is still a buoyant market in traditional medicines, which are
cheaper and readily available. Overall, the huge currency devaluation and subsequent rise in drug
prices have led to a sharp fall in demand, both for prescription drugs and for over-the-counter
products.
2.
The pharmaceutical sector is tightly controlled by the government
In 2006, there were around 272 pharmaceutical companies in Indonesia, including four state-owned
and 35 foreign-invested companies. The government has merge and the two largest state-owned
pharmaceutical companies, PT. Kimia Farma and PT. Indofarma, intended to privatize in 2005. In
early 2003 the government announced that the sale of a 51% stake in Kimia Farma, which was
included in the privatisation programme for 2003, would be delayed until 2004 because the company
needed more time to restructure. In May 2003, two subsidiaries of Kimia Farma were created to
operate in the retail and distribution sectors, and the company announced that it intended to focus on
the production of generic medicines, which account for 53% of production at present. The merger of
Kimia Farma and Indofarma is to take place after the two companies have completed restructuring.
Having reported a large loss in 2002, Indofarma forecasted falling sales in 2003 because of the
governments decision not to raise the prices of generic medicines, which account for 85% of
Indofarmas output.
3.
Local pharmaceutical companies tend to be small-scale
The majority of pharmaceutical companies are small, manufacturing a limited range of products, and
profitability is low; companies have been hit hard by the recent increases in utility prices. Foreignowned companies have threatened to relocate to cheaper locations such as Thailand following the
utility price increases. Local manufacturers lack the financial resources to undertake research, and
generally either produce drugs under licence from foreign drug companies or distribute generic drugs.
The local pharmaceutical industry is currently operating at 60-70% of capacity, as demand has
suffered in the wake of the financial crisis. The industry is heavily controlled by the government,
which encourages the production and distribution of generic drugs.
During the five years, from the start of the economic crisis in 1997 until 2001, 25 local pharmaceutical
manufacturers went bankrupt, leaving more than 12,500 employees jobless. Strict competition due to
a small market size, complicated import clearance and the slump of the Indonesian Rupiah against the
US dollar, which until now has yet to be stable, have been the bitter pills for the local industry to
swallow. Most of the bankrupt companies have shifted their business to produce food supplements or
medicinal herbs, which have less crowded markets.
- 11 -
According to GP Farmasi (Indonesian Association of Pharmaceutical Companies), there are currently

(end 2007) 272 pharmaceutical producers operating in the country compared to 223 in early 1997.
4.
Market size and characteristics
The pharmaceutical market is very complex and goes together with various linkages, starting from the
agent, merchant organization, company and individual. For the domestic pharmaceutical market, at
least there are three components that are involved. The first is the consumer or medicine user
community. The second is the medicine producer or factory. The third is the intermediary who links
between consumers and producers. The presence of the last component is different from the market of
other products. In addition to the normal marketing supporters like distributors, dispensaries or
drugstores, there are also medical doctors who recommend the use of certain medicines.
Such diffrerence makes consumers position weak in deciding what medicines to buy. The decision to
buy or economical consideration does not come from consumers or patients. The role of doctors is still
very predominant in determining what brand and type of medicines are to be taken.
Meanwhile, the nature of the resulted product is closely related to human safety and some medicine
factories find it hard to comply with these requiremenst. Nevertheless, the national pharmaceutical
market is still growing impressively from Rp 7.4 trillion in 1999 to Rp 18.05 trillion in 2003. It even
reached Rp 22.5 trillion in 2004. In 2005, the market of Indonesian pharmacy reached Rp 24 trillion,
of which Rp 23 trillion coming from the regular growth and Rp 1 trillion coming from the additional
contribution fund of the government subsidy program for families as a compensation from the effect
of fuel-oil (BBM) increase.
In the 2004-2006 period, overall drug market grew by around 9% per year, lower than average growth
in 2001-2003. The market value for 2005 was around Rp 23 trillion (US$ 2.28 billion)2. The
Indonesian market value is bigger compared to other South-East Asian countries such as the
Philippines (US$ 1.39 billion), Thailand (US$ 1.25 billion), Vietnam (US$ 447 million), Malaysia
(US$ 403 million) and Singapore (US$ 342 million).
However, if compared to the average consumption of drugs per person, Indonesia is the lowest. With a
population of 238 million, the country's consumption of drugs only reached US$ 7.1 per person, while
the Philippines was US$ 19.2 with a population of 78 million and Thailand US$ 23.8 with a
population of 63 million. It is estimated that the market size grew only by 5% in 2006 or two percent
below the 8% growth rate recorded in 2005.
In 2004, around 54% (equal 12.1 trillion) of the market of national pharmacy was controlled by 20
companies. Some 84% (equal Rp 18.9 trilion) of the market share was controlled by 64 companies.
The remaining 16% was shared among 141 companies. Around 70% of the market volume is
controlled by 35 foreign manufacturers including the world's giants Pfizer, Roche, Aventis, Novartis
and Mead Johnson. Local pharmaceutical companies, especially small- and medium-sized ones, face
immense competitive pressures. Local manufacturers are currently unable to compete with foreign
companies due to the lack of investment and research resources for inventing new medicines. Local
companies can only copy foreign companies and sell at lower prices by buying the formula and
changing the name of the drugs.
Excahnge rate: 1US$ equal Rp 9,200
- 12 -

To invent one new product, a multinational manufacturer can spend from US$ 350 to US$ 400
million. The annual budget allocated for research can reach US$ 2.5 billion, which is higher than the
Indonesian market value.
Local manufactures are a bit lifted in sales by their ability to export the cheap, copied drugs to other
poor or developing countries such as Myanmar, Vietnam, Laos, Cambodia in Asia, and Nigeria and
Uganda in Africa. However, the value is still small, around US$80 million per year, and mostly
composed of non-prescription drugs.
The country's five biggest pharmaceutical manufacturers in terms of market share are Kalbefarma,
Tempo Scan Pacific, Kimiafarma and Indofarma. The last two companies are owned by the state, and
according to recent media releases (ECFIN3 2007) there is serious consideration to merge the two i.e.
Kimiafarma (stronger and profitable) and Indofarma (loss making generics producer) to reduce
unnecessary competition between state-owned companies.
PT Kalbefarma and Tempo Scan Pacific are big players in the OTC market. PT Kalbefarma recorded
revenue of Rp 6 trillion in 2005-2006, of which 76% from OTC and 24% from ethical. Meanwhile,
PT Tempo Scan Pacific also dominated the OTC market with analgesic products like Bodrex and
Oskadon.
Around 95% of the raw material for the industry is imported, which makes the timing of import
clearance very important for a company to run efficiently and compete with others, foreign or
domestic.
Moreover, the local industry is also threatened by cheaper, smuggled and fake products which have
continued to pour into the country since 1998, usually aided and abetted by paid off officials.
The dependency of the pharmaceutical industry on imported raw materials has made it vulnerable to
the currency fluctuations against the US dollar, as was evident in the skyrocketing API (active
pharmaceutical ingredient) prices during the economic crises that saw the Rupiah tumble against the
US dollar. Such vulnerability leads to inflexible production costs and price of products.
Pharmaceutical prices in Indonesia have increased by 200% since late 1997, far lower than the 500%
increase in operating costs during the same period.
5.
Recommendations
The new entrant to the Indonesian marketplace could initially choose to either export finished
products through established channels, thereby minimizing resource commitments to the market. A
scale-up could then follow by either setting-up a pharmaceutical plant fed through raw materials
produced abroad (in a captive plant or procured from third party suppliers) or by establishing a basic
ingredient plant that feeds the domestic industry and markets outside of Indonesia.
6.
Prospect
The national pharmacy market has been increasing, from Rp 9.94 trillion in 2000 to Rp 24.17 trillion
in 2007, with the non-ethical drugs (i.e. generic) sales worth Rp 2.66 trillion or 11% of total national
pharmacy market. Although the Indonesian income per capita has been decreasing since the crisis in
1997, the demand for generic drugs is low compare with other Asian countries i.e. Hong Kong (25%),
Singapore (25%), Taiwan (70%), Malaysia (20%) and Thailand (25%).
3
ECFIN is Economic and Finance Consultant
- 13 -

The implication is that the over the counter market offers an increased potential. In 2006, the national
ethical medicine market reached Rp 12.8 trillion or about 55% of the national pharmaceutical market.
Therefore, competition between foreign and domestic companies has increased.
- 14 -
III.
MAIN REPORT
A. Industry overview
The domestic pharmaceutical industry consists mostly formulation or assembling industry. There are
only a few companies classified into fully manufacturing companies and less than 5 companies
producing pharmaceutical basic materials. This situation is driven by the fact that expenditures on
research and development of local pharmaceutical companies are very small i.e. around 1-2% of total
sales as compared to some 15-16% for multinational companies.
Machines or production facilities used are universal machines processing basic materials such as
grinding machines, mixers and machines producing tablets, capsules, or other types of packaging or
forms. In the production of medicines with single basic material such as generic medicines, a factory
uses only simple equipment, since the basic materials do not need to be processed.
Despite doubt that begins to haunt most of the countrys economic sectors in ability to compete in
open market competition, the confidence is strong that the pharmaceutical industry will continue to
grow and expand. The confidence was strong despite the fact that several years ago, the industry,
which still heavily depends on import for basic materials, suffered a setback by the crisis with the
sharp fall of the rupiah. Around 56% of the 272 pharmaceutical companies grouped in the Indonesian
Association of Pharmaceutical Companies (GPFI) were forced to slow down operations to 50% of
their installed capacity because of the soaring prices of imported basic materials.
The production fall was caused by the difficulties in basic material procurement with the soaring value
of dollar against rupiah and slump on the domestic market with the weak purchasing power of the
consumers. In addition, the costs of procuring packaging such as aluminum foil, plastic and bottle
contributed to an increase in production cost for pharmaceutical products. The difficult condition
rendered the industry a big blow, especially for Indonesian private companies. Foreign joint venture
companies, which total around 40 in number, fared well despite the crisis as they have support from
their principals abroad. The four state-owned companies also fared relatively better with the support
from the government in basic material procurement.
B. Production capacity
Pharmaceutical factories in Indonesia are "formulation" factories since most basic (active) ingredients
are imported. So far the country has produced a limited quantity and few types of basic (active)
ingredients.
1.
Geographical spread of pharmaceutical companies
GP Farmasi (Indonesian Association of Pharmaceutical Companies) members, to this point, only

include firms with legal operating licenses, comprising 272 manufacturers and the following is a
geographical spread of companies in the industry in Indonesia:
- 15 -
Province
D.K.I. Jakarta
Java (West)
Banten
Java (Central)
D.I. Yogyakarta
Java (East)
Bali
D.I. Aceh
Sumatra (North)
Sumatra (West)
Riau
Jambi
Sumatra (South)
Bengkulu
Bandar Lampung
Kalimantan (West)
Kalimantan (Central)
Kalimantan (South)
Kalimantan (East)
Sulawesi (North) & Gorontalo
Sulawesi (Central)
Sulawesi (North-East)
Sulawesi (South)
Maluku & Maluku (North)
Nusa (North-West)
Nusa Tenggara (North-East)
Papua
No. of factories
69
73
22
30
5
56
1
10
2
1
3
-
Total
272
Source: Indonesian Association of Pharmaceutical Companies, 2007
2.
The economic crises and production changes
During the five years of the economic crisis (1997-2001), 25 local pharmaceutical manufacturers went
bankrupt, leaving more than 12,500 employees jobless.
Strict competition due to a small market size, complicated import clearance and the slump of the
Indonesian Rupiah against the US dollar, which until now has yet to be stable, are the bitter pills for
the local industry to swallow.
Most of the bankrupt companies have shifted their business to produce food supplements or medicinal
herbs, which have less crowded markets.
Most of the surviving pharmaceutical manufacturers have facilities to produce at least 4 forms of
medicines: tablet, syrup, cream and caplet. Some of them also have facilities to produce medicines in
the form of drop, powder, granule, etc.
- 16 -
3.
Installed production capacity
The table below captures the installed production capacity of the Indonesian pharmaceutical industry.
No
1
2
3
4
Form of Products
Tablets
Oral Contraceptives
Capsules
Ointment/Cream
5
6
Lotion
Infusion
7
8
Inhaler
Injection
Talcum/Powder
10
Granules
11
Solution/Suspentions
12
13
14
Emulsion
Ovule
Syrups
15
Liquids
16
Others
Unit
Pieces-milion
Packs-million
Pieces-milion
Tons
Pot-million
Litres-000
Litres-000
Bottles-milion
Pieces-milion
Tons
Litres-000
Packs-million
Tons
Bottles-milion
Sachet-million
Pieces-milion
Tons
Sachet-million
Tons
Litres-000
Bottles-milion
Litres-000
Pieces-milion
Tons
Litres-000
Bottles-milion
Litres-000
Bottles-milion
Litres-000
Capacity
49,396
87
10,735
82
782
10
4,389
59
7
135
64
4
13,423
2
171
234
160
19
12,480
465
7
120
47
40
21
886
2,973
186
92
Based on the ways of dispensing them, the medicines are classified into two groups: ethical and nonethical medicines. Ethical medicines are those prescribed by doctors, while non-ethical medicines are
those sold over the counter (OTC).
4.
Type of medicines produced
Pharmaceutical manufacturers usually produce both ethical and non-ethical medicines. PT Kalbe
Farma for instance, produces ethical medicines/antibiotics such as Cefspan, Tanvid, Neuralgin and
OTC medicines such as Promag (stomach medicine), Cerebrovit (supplement), Procold (flue
medicine), Xon-C (vitamin) and Extra Joss (health drink). In addition to production, PT Kalbefarma
will continue to look for new licenses from abroad. The focus of PT Kalbefarma to the patented
medicines will also be followed with the effort to develop its market in ASEAN countries such as
Singapore, Malaysia, Thailand and the Philippines.
A state owned company, PT Kimiafarma, produces some 53 ethical medicines. Total sales in 2006
reached Rp 143 billion, an increase of 11.7% from 2005. The company said that performance will be
defended within the next year. The company also produces OTC medicines including OBH cough
syrups.
- 17 -
The following table shows type of medicines of selected pharmaceutical companies in Indonesia:
Company
Location
PT. Darya Varya Group
Bogor/West Java
PT. Indofarma
Cibitung/Cikarang
Bekasi
West Java
PT. Kalbe Farma
Bekasi
West Java
PT. Kimia Farma
Jakarta
Bandung (West Java)
Semarang
(Central
Java)
Mojokerto (East Java)
Medan (nort Sumatra
PT. Pyridam Farma
Cianjur west Java
Production Capacity/ Year

Type
Total
Unit
Tablet
70000000 Pcs
Syrup
8000000 Bottle
Hard capsule
10000000 Pcs
Soft Capsule
250000000 Pcs
Eye drop
150000 Bottle
Liquid & powder
8500000 Vial/ampute
Contact lens care
6075000 Bottle
Sterile ban aid
710000 Envelope
Granule
15000000 Sachet
Tonic/Vitamin
Tablet
3350000 Pcs
Capsule
465000 Pcs
Syrup
11000 Bottle
Cream
10500 Tube
Powder
18000 Sachet
Injection
36000 Ampules
Eye drop
3000 Bottle
Vial powder
3000 Bottle
Tablet
360000000 Pcs
Capsule
60000000 Pcs
Liquid
3000000 Bottle
Cream
600000 Tube
Injection
3600000 Ampules
Tablet
2249720 000 Pcs
Caplet
636599 000 Pcs
Cream
Capsule
Soft Capsule
Granule
Dry syrup
Syrup/Suspension
Eye drop
Injection
Contraception tablet
Tablet
Powder
Yodium
Kalium Yodat
Ferro sulphat
Oil
Qiunne & salt
AKDR
Tablet
Capsule
Syrup
Granule
Cream
- 18 -
163
332000
83280
92
125
1010
11
18
18800
475
145
18
70
5400
Ton
000 Pcs
000 Pcs
Ton
Ton
000 Liters
000 Liters
000 Liters
Siklus
Ton
Ton
Ton
Ton
Ton
1750
115200000
32256000
1105920
552960
460000
Unit
Mill Pcs
Mill Pcs
Bottle
Sachet
Tube
PT.Tempo Scan Pacific
East Jakarta
Cikarang West Java
Tablet
Capsule
Liquid
External use
PT. Bristol Myers Squib

Indonesia
Bogor/West Java
PT. Bayer Indonesia
Jakarta
Liquid
Cream
Solid
Granule
Tablet
Capsule
Liquid
Cream & Ointment
Tablet
Capsule
Syrup
Cream & Ointment
Eye lotion
Injection
PT. Dankos Laboratories
Jakarta
2.4E+12
180000000
720000
72
240
60
270
2218
1420000
49000000
21000000
580000000
30600000
8000000
4000000
800000
400000
Pcs
Pcs
Liters
Ton
Ton
Ton
Ton
Ton
000 Pcs
Bottle
Tube
Pcs
Pcs
Bottle
Tube
Bottle
Bottle
Source: Department Of Health
5.
Cooperation with multinational companies
Many local manufacturing companies produce medicines under special production license from
overseas manufacturers, particularly for ethical products.
Of some 270 types of products produced by PT Kimia Farma, about 40 are produced under production
license agreement with their overseas principals. Some of their principals are Heinrich Mack Nacht
GmbH & Co. KG.
A major private national company, PT Kalbe Farma, has also concluding production agreement with
major multinational pharmaceutical companies including Bristol-myers Squibb, Warner lambert-Parke
Davis, from USA, Fisons Pharmaceuticals plc dan Smith Kline Beecham plc of UK, Asta Pharma
C. Market characteristics
1.
Background
Indonesia is the fourth most populous country in the world: the population is estimated to be around
238 million (2007), with an annual growth rate of 1.1% per annum. The population rate is likely to
double by year 2040 giving a population of some 400 million people. Some 56% (or 120 million) of
the population is aged under 25, while only 3.8% (or 7.5 million) are aged over 65, and 3.5 million
babies are born annually, at a rate of 7 per minute.
There have been some dramatic improvements over the last 30 years: life expectancy has risen from
42 to 69 years; infant mortality has declined from 140/1000 to 54/1000; and the crude death rate has
halved from 14/1000 to 7/1000. Universal Child Immunisation (UCI) was achieved in 1992, but some
preventable diseases such as polio, diphtheria and measles remain prevalent. Malaria has largely been
controlled on Java and Bali.
- 19 -

Malaria disease has been controlled by annual parasite incidence (API) of Jawa-Bali and annual
malaria incidence (AMI) for out of Jawa-Bali. The number painfulness of malaria has decreased from
21.2/1000 in 2000 to 18.94/1000 in 2005; the prevalence of tuberculosis being 107/100 000; and
Vitamin A deficiency being almost eliminated.
But problems remain. Degenerative diseases, such as Cancer and Cardiovascular diseases, which are
the two greatest causes of death, are growing rapidly; Hepatitis B is carried by 60 million people;
cataracts and iodine deficiency remain common (70% of blindness is due to cataract) and AIDS is
spreading rapidly, reaching 2.65/100 000.
A lack of confidence in the domestic health system traditionally resulted in many people seeking
medical services outside Indonesia. However this has reduced dramatically with the continuation of
the economic crisis. Patients who may have previously sought overseas treatment are now being
treated in private hospitals in Indonesia, and patients who may have previously been able to afford
private treatment in a private hospital are now seeking treatment at the state run hospitals. Latest
health figures state that there are 1,258 hospitals in Indonesia, providing a total sum of around
136,766 beds. But up to 600 new private hospitals are still needed. Recent legislation allows foreign
medical personnel to practice in Indonesia, albeit on a restricted basis.
The economic crisis in 1997 had a major impact on the healthcare sector. But the provision of primary
healthcare, as part of the social safety net programme, is still a priority for the Government of
Indonesia focusing particularly on mother and child healthcare and nutrition. Government funds for
new equipment and projects are still extremely scarce, although multilateral donor programmes do
include healthcare projects and opportunities within these do exist. A market for refurbished medical
equipment also exists.
Preparations for the Governments regional autonomy are in process and this includes the Ministry of
Health. Decentralization will give responsibility to the local district level (of which there around 300
nation-wide) and this process for health provision is now completed. The total budget allocation of the
Department of Health in 2005 amounted to Rp 10.67 trillion and only 6.52 trillion or 61.09% of total
budget were spent. The allocation consists of 5.08 trillion (74.18%) for center government and 2.75
trillion (25.82%) for local government.
The aim is to improve the health status of people by enhancing service coverage, quality and
utilization of health facilities. The objective is to assist local governments, health professionals and
communities in identifying health needs and priorities, developing locally appropriate solutions and
improving health services quality. The project will comprise building and training activities, physical
investments to improve service quality, and support for locally adapted health sector reforms.
The Ministry of Health (DEPKES) is currently in the process of drafting new regulations to introduce
a compulsory "National Health Insurance" scheme (JPKM) in the form of a managed care system. If
this legislation is adopted it may be seen, in some quarters, as an additional Government Tax, and a
further dispensation of responsibility by DEPKES. The national insurance premium is likely to be 6%
for all employers regardless of whether they already have a medical scheme for their staff.
There are more than 272 pharmaceutical companies in Indonesia. As a result of the economic crisis,
there has been a rise in the popularity of generic medicine and a reduced demand for branded drugs.
Approximately 90% of raw materials for pharmaceutical production are imported and therefore with
the weakening of the Rupiah companies have been forced to raise their selling prices leading to a
decrease in sales volume.
- 20 -

These companies have experienced difficulties during the post economic crisis era due to the reduced
demand for branded drugs, in addition to recent problems with official drug registration by the
Ministry of Healths Food and Drug Division. There are three state-owned pharmaceutical companies
in Indonesia, all of which are currently in line to be merged into one SOE by the Governments
overall privatisation by 2004. These are PT Indofarma, PT Kimia Farma4, PT Phapros and PT Bio
Farme. The four companies are in the preliminary stage of synergising their businesses. In the longer
term, the Government plans to sell shares in the single company that will result.
Eventually opportunities are likely to be good in most areas of the health sector including hospital
design and construction, hospital management, education and training and the supply of equipment.
Suppliers are urged to maintain contacts within the market.
2.
Segmentation by type of product
Consumption of generic drugs in Indonesia (11 %) is relative low if compared to Hong Kong 25%,
Singapore 25 %, Taiwan 79 %, Malaysia 20 %, Thailand 25 % and Germany 40%. In 2006, generic
drug sales reached around Rp 2.66 trillion or 11 % of total national pharmaceutical market but the
market share of generic medicines grew by 41.3% annually on average. The fast growth showed that
demand for generic medicines has continued to increase especially amid the weak purchasing power
of the people. The Drug and Food Control Agency (BPOM) has continued to increase supply of
generic medicines as the government carries an obligation to meet the medicinal requirement of the
people especially low-income people. The generic medicines are much cheaper than branded products
and affordable by many people, because they dont bear any promotion cost as well as research and
development cost. For illustration, a generic cough medicine of Indofarma is only Rp 130 per tablet of
35 mg, while similar branded product can be as high as Rp 1,319 per tablet.
Average growth rate of generic medicines in 2005-2006 period is 10.65%, Eventhough, the generic
medicine is very cheap compared with the branded products but consumption of generic medicines in
2007 was only 9.7% of the pharmaceutical market in value. This degradation is quite sharp compared
with the average growth rate of generic medicines in 2005-2006, which reached 10.65%. In quantity,
generic medicines exceeded both OTC and ethical medicines.
GP Farmasi has asked the government to allow the market to determine the prices of generic
medicines with logo to attract the private sector to invest in generic medicines industry. Currently
state-owned pharmaceutical companies control 70% of procurement of generic medicines in the
country.
Among 80 private companies licensed to take part in the production of generic medicines only around
10% are active in producing generic medicines.
PT Kimiafarma and Indofarma have been mergered
- 21 -
Development of Medicine Market by Type of Product

1999-2006
Branded
(Rp Trillion)
%
1999
6.50
87.84
2000
8.58
88.27
2001
11.03
87.54
2002
13.47
88.62
2003
15.25
88
2004
n.a
n.a
2005
14.68
n.a
2006
13.96
(5)
Source: various ources (processed)
Year
Generic
(Rp Trillion)
0.9
1.14
1.57
1.73
2.08
n.a
9.01
10.21
%
12.2
11.7
12.5
11.4
12
n.a
n.a
11.7
Total
(Rp Trillion)
7.4
9.72
12.6
15.2
17.33
20.00
23.69
24.17
The competition is quite tight between pharmaceutical producers in the country both local and
multinational companies. Therefore, producers resort to a number of strategies in order to survive. The
most popular method is advertising through the mass media.
The advertising cost is high and it is major element determining the price. Producers estimate that
promotional campaigns account for 30% of the price of a pharmaceutical product.
3.
Consumption
The country's overall drug market grows by around 20% every year, but the value is still small. The
market value for 2006 was around Rp 24.1 trillion (around US$ 2.62 billion). However, if compared
to the average consumption of drugs per person, Indonesia is the lowest.
With a population of 238 million, Indonesias consumption of pharmaceutical drugs only reached
US$ 8 per capita (2004), US$ 8.8 per capita (2005), US$ 9 per capita (2006). This is relatively small.
The low consumption follows the high prices of medicines relatively to the average incomes and
consumers' weak purchasing power. Many people prefer to use traditional medicines, which are
cheaper and readily available. Sales volumes for prescription drugs dropped markedly when the
economic crisis began in 1997 and have not yet fully recovered. Many Indonesians are now tending to
rely only on self-medication as prices of prescription medicines and OTC products have also
increased.
4.
Potential consumption
Prior to the economic downturn, the improved health and increased per capita income of Indonesians
led to increased demands to provide better quality health care and health care products. Yet,
increasing awareness could not, by itself, answer all public health problems.
After the crisis hit the country, the situation changed dramatically. The hardships of 1998 today
remain fresh in many people's minds. In that year the Rupiah fell nearly 80% from its level in 1997.
Combined with an annual inflation rate of 10% at the end of 1998, the Rupiah's real depreciation then
was one of the largest experienced by any nation in the post-war era.
- 22 -
Some of the first inputs into public health to be affected by the 1998 depreciation were
pharmaceuticals (including vaccines and contraceptives), of which an estimated 60 to 80% are
imported. Limited surveys conducted by World Bank indicated that drug prices increased by 200 to
300% between November 1997 and March 1998.
Many people here prefer to use traditional medicines, which are cheaper and readily available. Sales
volumes for prescription drugs dropped markedly when the economic crisis began in 1997 and have
not yet fully recovered. Many Indonesians are now tending to rely only on self-medication as prices of
prescription medicines and over-the-counter (OTC) products have also increased.
The Indonesian pharmaceutical market has developed well in recent years. Exports have shown a
steady positive trend in the 2005-2006 period. The growth has been driven by OTC, that is ried at 1%
during that period, and domestic manufacturers estimate continuous growth in 2007. There are
possibilities of merger between leading companies that are PT Bayer and PT Schering-Plough
Indonesia. It is hoped that investment from abroad would increase, thus strengthening the
pharmaceutical industry and prospects for the market, which are good in the short time.
5.
Key players
Based on the sales figures of the last two years (2005-2006), a national private company, PT Kalbe
Farma, enjoyed the highest sales in Indonesia, followed by PT Tempo Scan Pacific, PT Kimia Farma,
and PT Indofarma.
The following table presents key players in the local market for pharmaceutical and their estimated
market share.
Total Sales of Medicine of Selected Pharmaceutical Prdoucers in Indonesia

2004-2006 (Million Rupiah)
Company
PT. Indofarma
PT. Darya Varia Group
PT. Kimia Farma
PT. Kalbe Farma
PT. Pyridam Farma
PT. Schering-Plough Indonesia
PT. Tempo Scan Pacific
PT. Merck
PT. Bristol Myers Squibb Indonesia
2004
589,522
426,796
1,925,990
5,042,818
33,969
112,005
2,371,553
373,341
221,595
Source: ECFIN, 2007
- 23 -
2005
684,040
540,437
1,816,433
5,870,939
39,640
132,729
2,497,874
385,345
166,816
2006
1,028,678
576,669
2,189,715
8,071,550
61,337
123,758
2,729,224
487,601
243,776
D. External Trade
After a lengthy period of government policies promoting import substitution, companies have been
able to meet all essential medical needs in Indonesia. Since the late 1980s, only a few products have
needed to be imported. According to the Indonesia Association of Pharmaceutical Companies (GP
Farmasi), there were 9,246 pharmaceutical products of different formulas being produced in the
country, including 2,890 with generic names and 6,356 with trade names.
95% of basic (active) ingredients for Indonesia's pharmaceutical factories are imported. This is the
case largely because the government (in a bid to reduce dependence on imports) has required foreign
joint venture companies to produce at least one basic ingredient domestically. This regulation,
however, could not be effectively enforced because only a few joint venture companies were able to
comply with it. A producer of basic ingredients faces many problems. For one thing, producing
pharmaceutical basic ingredients requires high technology and expensive research facilities. In
addition, the principal companies abroad may not be anxious to transfer their technology to their
Indonesian partners. However, investors have shown genuine interest in building factories to produce
antibiotic basic ingredients in Indonesia.
1.
Imports by country of origin
Indonesia imports pharmaceutical materials from various countries particularly from China, the
United States, France, Japan and Germany. These countries contributed to some 56% of total
Indonesias imports of pharmaceutical products and materials. In the 2005-2006 period, China was the
biggest supplying country (17.6%) followed by the United States (12.9%) and France (9.78%).
Besides China and Japan, the main Asian suppliers also include Korea, India and Singapore. Imports
from India have increased from US$ 4.4 million (2005) to US$ 8.4 (2006) or about 3.5% to total
Indonesias imports of pharmaceutical material and products (HS codes 22936.10.000-3004.90.929).
2.
Imports by volume
Imports account for roughly 95% of the basic ingredients needed for the country's pharmaceutical
industry. By contrast, imports (legal) of pharmaceutical products account for only 2% of the total
demand (see table below).
- 24 -
Import Pharmaceutical Products by Country of Origin

2005-2006 (000 USD)
Country of Origin
Germany
US
Swiss
France
China
Japan
Italy
Singapore
Netherlands
UK
Korea
Belgium
Spain
India
Source:Statistics, Indonesia
2005
2006
9,780
15,641
7,418
11,679
19,938
9,193
5,761
5,813
5,925
5,490
6,418
1,531
3,673
4,339
7,246
14,745
8,655
11,166
21,363
10,506
7,626
6,773
9,508
3,736
7,575
2,043
2,881
8,430
Imported products and basic ingredients can be divided into the following groups: antibiotics,
hormones, glycoside and organo therapeutic gland antisera, provitamins and vitamins. Basic
ingredients for drugs are imported from China, U.S., France, Japan, the Netherlands, Italy, Germany,
Australia and others.
3.
Raw materials
Type of materials consumed and volume of consumption Indonesia depends on imports for 85%-90%
of its pharmaceutical basic materials. Manufacturing of medicines is dominated by foreign investment
(PMA) companies. Local companies operate only as formulators assembling imported basic materials
already processed.
Imports of finished pharmaceutical products and basic materials could be estimated from the fact that
the country depends on imports for 85%-90% of its pharmaceutical basic material requirement. The
Central Bureau of Statistics (BPS) puts imported basic materials and finished products into two
groups namely medicinal & pharmaceutical products and medicaments including veterinary
medicinal.
Based on data at the Pharma Materials Management Clubs (PMMC) and various sources, the
countrys imports of pharmaceutical basic materials were valued at Rp 2.65 trillion in 2003, decreaing
by 3.9 % to Rp 2.55 trillion in 2006. Therefore, in the 2003-2006 period, imports of pharmaceutical
products tended to decrease from US$ 331 million in 2003 to US$ 122.3 million in 2006.
The rupiah stability lately helped recover pharmaceutical industry from the lingering crisis. Imported
finished products of medicines are mainly special kinds of medicines used little in the country.
Imports are therefore small in value compared with imports of basic materials. Imported products of
finished medicines are mainly ones not commercially feasible or profitable to be produced in the
country such as anti cancer medicines and immuno-globulin.
- 25 -
Estimated Requirement and Imports of Pharmaceutical

Basic Materials by Value, 1999-2006
Value
Rp Trillion
1999
1.29
2000
1.7
2001
2.14
2002
2.33
2003
2.65
2004
n.a
2005
2.21
2006
2.55
Source: Several sources
Growth
%
31.8
25.9
8.9
13.7
n.a
n.a
n.a
Year
4.
Import
Rp Trillion
1.1
1.45
1.82
1.98
2.25
n.a
n.a
1.55
Imports of antibiotics basic materials
Antibiotics are one of the main pharmaceutical basic materials imported by the country. Based on a
survey by Data Consult, three of 11 pharmaceutical companies surveyed are major importers of
antibiotics namely PT Kalbe Farma, PT Combiphar, and PT Sanbe Farma. PT Kalbe Farma imports
amoxycillin, PT Combiphar imports amoxycillin and ampicillin and PT Sanbe Farma imports
ofloxacin, oxytetracycline base, rifampicin, roxythrimycin, and tetracycline HCL.
Paracetamol, an active ingredient for analgesics is also imported in large quantity. Paracetamol
dominates 85% of imports of analgesic basic materials. Paracetamol is imported mainly from China.
The only company producing paracetamol, PT Riasima Abadi, which came on stream in 1982 could
not meet domestic requirement. The company was almost idle through 1992 and 1993 because of
failure in market competition. Earlier the company enjoyed protection with import restriction and
tariff barriers. Now, however, the protection has been removed and the import duty has been reduced
on that material.
Among the 11 companies surveyed, two are main importers of paracetamol namely PT Bintang
Toedjoe and PT Dankos Laboratories. The two companies also imports other analgesic basic materials
namely acetosal.
- 26 -
Import of Antibiotics Basic Materials 2004-2006

Types of Antibiotics
6- APA non sterile
Ampicilin non sterile
Amoxyline non sterile
Other types of penicillin
Strepthomycin and their derivatives; salt
there of
Tetracylin and their derivatives; salt there of
Chloramphenicol and their derivatives; salt
there of
Erythromycin and it's derivatives; salt there
of
Rifampicin
Cephalosphirin and it's derivatives; salt
there of
Quinolone and it's derivatives; salt there of
Other antibiotics
Total
2005
000 US$
Tons
4,026.6
158.8
733.4
18.6
n.a
n.a
2,443.4
39.0
2006
000 US$
Tons
3,261.9
510.1
2,018.5
73.3
12,476.6
567.2
1,782.5
93.6
145.0
3,066.1
9.8
297.3
378.1
3,053.8
11.5
254.1
3,066.9
137.7
4,318.4
177.8
3,501.6
4,724.3
30.0
150.3
29.2
2,481.7
0.015
46.2
8,706.4
3,735.4
5,447.9
39,597.0
44.9
123.2
420.4
1,430.0
11,682.7
3,727.4
9,438.0
54,468.8
86.7
121.0
618.7
1,255.7
Source: Statistics Indonesia
- 27 -

Import of Pharmaceutical Basic Materials/Finished Products
by 10 Pharmaceutical Companies Per Annum
No
1
9
10
Name of company
Bintang Toejoe, Co
O-Acetylsalycilic Acid
Paracetamol
Combiphar, Co.
Amoxyline
Ampicilin
Cefadroxil 1 Monohidrate
Cotrimokxazole
Simvastatin
Dankos Laboratories, Co.
O-Acetylsalycilic Acid
Paracetamol
Indofarma, Co.
Licenced Medicine
Herbal Medicine
Interbat, Co.
Atenolol Tablet
Cefixime injection
Hyoscine
N-Butylbronicle
Injection
Ketoconazole tablet
Losartan tablet
Lovastatin tablet
Tenoxicam caplet
Thiampenicore capsule
Kalbe Farma Co.
Amoxyline
Attalpulgite coll
Coffein
Hydrotalcite
Magnesium hydroxide
Paracetamol
Vitamin C
Phapros, Co.
Ampicilin
Amoxyline
Tetracyline
Antalgine
Mefenemik Acid
Pharos Indonesia, Co.
Antineoplastic drugs
Antidiabetic drugs
Antibiotic drugs
Biotech products
Hormone products
Lowering Cholesterol agents
Pratapa Nirmala, Co.
Sanbe Farma, Co.
AC-Di-Sol
Amoxyllin
Sodium
Sterile
Crystalin
- 28 -
Quantity
n.a
n.a
n.a
n.a
n.a
n.a
n.a
n.a
n.a
On Demand
On Demand
On Demand
On Demand
On Demand
On Demand
On Demand
On Demand
On Demand
On Demand
50 MT
70 MT
43 MT
280 MT
210 MT
583 MT
200 MT
50 Tons
50 Tons
30 Tons
20 Tons
20 Tons
n.a
n.a
n.a
n.a
n.a
n.a
600 Kgs
900 Kgs

5.
Sources of raw materials
Imports of pharmaceutical products and basic materials have been made from advanced nations such
as France, Germany, Britain, Swiss, the United States, Japan, India, etc. as most of the large
pharmaceutical companies in the country are joint ventures with foreign companies from those
countries. Their principals abroad guarantee supplies of basic materials. Substantially, large imports
have also been made from China and Singapore.
Company
Kalbe Farma, PT
Tempo Scan Pacific, PT
Indofarma, PT
Bayer Indonesia, PT
Darya Varia Group, PT
Pyridam Farma, PT
Source: Several sources
6.
Souces
Local
Import
25
75
20
80
10
90
15
85
12
88
10
90
Imported raw material from

Japan, US, Poland, China
Japan, US, China, India, Germany, Mexico
China, India, Germany, US, Netherland
Grermany, India, US, Netherlan, Swiss, etc
China, Japan, India, Germany, US, Netherland, French, Swiss, Italy
China, Japan, Germany, US, Netherland, Swiss, Singapore, etc
Exports
Despite heavy dependence on imports for basic raw materials, Indonesia has exported pharmaceutical
products for a long time. However due to stiff competition from countries like China (an active
ingredient supplier to Indonesia), and India (with its prowess in generics), exports have been rather
miniscule. Consequently, the BPS (Statistics Indonesia) and Bank Indonesia do not publish as detailed
statistics on export of pharmaceuticals, and it is reflected as Others under the category of Industrial
Exports.
ExportValue of Pharmaceutical Products 1997-2006
(in 000 US$)
Year
Export
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
60,390.0
44,400.0
61,030.0
59,870.0
69,920.0
97,980.0
100,000.0
153,808.3
12,827.4
65,540.5
Source: Statistic Indonesia, 2006
The adjoining table is an extract of data processed from figures published by the Pharmaceutical
Products and Food Supervisory Board (B-POM), and other secondary sources.
An examination of the customs data indicates that Indonesia mainly exports quinine and its derivates
as well as herbal medicines. Exports of quinine and its derivatives mainly go to Germany, U.S.,
Singapore, U.K., Vietnam, Spain, and Canada. Exports of herbal medicine go to Pakistan, Iran, and
Hong Kong (the three largest markets for Indonesian herbal exports) and others including Bangladesh,
Singapore, Malaysia, Libya, Taiwan, Yemen, the Netherlands, and Germany.
Exports of Traditional Herbal Medicine reach US$ 1,630 thousand (2006) from 1,601 thousand
(2003).
- 29 -
Based on the export data from BPS (Central Bureau of Statistics), exports of traditional drugs (Jamu)
and traditional medicines in the form of modern packaging have shown an increase, although
relatively small. As an illustration: in 2003, exports of traditional drugs has just reached US$1,601
thousand but in 2006, only US$ 1,629 thousand. Traditional drugs are mainly consumed by the
Indonesia Worke Force (TKI-tenaga kerja Indonesia) in several export destination countries.
HS Code
300390100
300490100
Description
Prep.2 or More Mix Prod. Od Veg. Amlor Mnrl Subs. In Measured Dosage
Prep.2 or More Mix Prod. Od Veg. Amlor Mnrl Subs. NO List In Measured Dosage
Total
2003
000 US$
2006
000 US$
98.7
1,005.90
1,502.20
624.02
1,600.90
1,629.92
Source: Indonesian Statistic, 2006
Projection on Sales of Traditional Drug, 2010

Total Sales
(Rp Trillion)
5.0
6.0
7.2
8.5
10.0
Year
2006
2007
2008
2009
2010
Source: KADIN Roadmap 2010
7.
Exports by type
As indicated by the following table, Indonesias export of pharmaceutical consists primarily OTC
products. As many of local companies producing medicines under special license agreement with
overseas principals, the local company has not freedom to export their products. The license usually
defined for the local market territory. The company should obtain approval from their principal abroad
to market their products outside Indonesia. It is not easy, since their foreign principals usually have
their own subsidiary companies in the export destinations.
In the meantime, it takes some times to register the export products in the country of destination. In
the United States, exporters should acquire certificate from FDA Inspections.
Countries of destination of Indonesias exports include other ASEAN countries, Japan, Korea, China,
Malaysia, India, the United States, the Netherlands, France, Germany, Switzerland and others. One
notable export commodity is quinine. PT Kimia Farma is the only quinine producer. Exports of
Quinine was recorded at some 1,255.7 tons valued at US$ 54,468.8 thousand in 2006.
- 30 -
Export Pharmaceutical by Types 2004-2006

HS Code
2004
Description
kg
2005
USD
kg
2006
USD
Kg
USD
2936.10.000
Provitamin unmixed
2936.21.000
Vitamin A and their derivatives
2936.22.000
2936.24.000
Vitamin B1 and It's derivatives

D-OR DL- Pantothenic Acid (Vitamin B3 or B5 and it's derivatives
2936.25.000
Vitamin B6 and it's derivatives
2936.26.000
Vitamin B12 and it's derivatives
2936.27.000
Vitamin C and it's derivatives
2936.28.000
Vitamin E and it's derivatives
2936.29.000
Other Vitamin and their derivatives
2936.90.000
Other and including Natural Concentrate
2937.10.000
Similar Hormons and their derivatives
n.a
n.a
n.a
n.a
n.a
n.a
2937.29.000
Other adrenal cortical hormones
n.a
n.a
n.a
n.a
n.a
n.a
2937.91.000
Insulin and it's salts
n.a
n.a
n.a
n.a
n.a
n.a
2937.92.100
Raw material for contraceptives
n.a
n.a
n.a
n.a
n.a
n.a
2937.92.900
Other hormones natural or reproduced by synthesis
n.a
n.a
n.a
n.a
n.a
n.a
2938.10.000
Rutoside (rutin) and it's derivatives
n.a
n.a
n.a
n.a
n.a
n.a
2938.90.000
Other glycoside
227505
544338
414474
672368
415159
578764
2939.21.000
Quinine and it's salts
186812
8960085
n.a
n.a
177798
1E+07
2939.29.000
Other alkaloides of cinchona
n.a
n.a
2400
5088
n.a
n.a
2939.49.000
Other ephedrines and their salts
n.a
n.a
n.a
n.a
n.a
n.a
2939.50.000
Theophyline and aminophyline and their derivatives, salts, there of
n.a
n.a
n.a
n.a
n.a
n.a
200
2700
n.a
n.a
n.a
n.a
128411
843810
n.a
n.a
224807
2E+06
1000
39000
n.a
n.a
n.a
n.a
n.a
n.a
n.a
n.a
115
4650
2939.90.000
Other vegetables alkaloids
2940.00.000
Sugars, chemically pure, other than sucrose, etc;

sugar either and their salts
2941.10.100
6-APA non sterile
2941.10.200
Ampicilin non sterile
4453
37496
n.a
n.a
27
80
n.a
n.a
65
7475
15604
82989
7418
261932
566
8541
4057
99654
n.a
n.a
n.a
n.a
n.a
n.a
37
826
1525
24934
400
5940
7772
593197
6270
474237
9516
657817
33261
613997
181574
485292
161111
224992
n.a
n.a
712
3500
6010
10497
10043
101654
10488
150446
3305
87992
8737
182134
30145
533283
25538
74812
2941.10.300
Amoxyline non sterile
49233
200570
n.a
n.a
n.a
n.a
2941.10.900
Other peniciline
44000
14470
9482
178235
n.a
n.a
2941.20.000
Streptomycine and their derivatives, salts there of
12525
12035
n.a
n.a
n.a
n.a
2941.30.000
Tetracyline and their derivatives, salts there of
n.a
n.a
n.a
n.a
n.a
n.a
2941.40.000
Chloramphenicol and it's derivatives salts there of
15398
30424
n.a
n.a
n.a
n.a
2941.50.000
Erythromycine and it's derivatives, salts thereof
n.a
n.a
n.a
n.a
n.a
n.a
2941.90.100
Rifampicin
n.a
n.a
115
4681
n.a
n.a
2941.90.200
Cephalospirin and it's derivatives, salts thereof
174
60443
83
31618
n.a
n.a
2941.90.300
Quinolone and it's derivatives, salts thereof
227
12522
30
25
1700
2941.90.900
Other anthibiotics
15854
319840
75645
938351
84072
654038
2942.00.000
Other orgnaic compounds
12512
57417
49345
165424
16700
150531
3001.10.000
Glands and other organs, dried, wheter or not powdered
109497
372372
5791
13823
18168
12288
3001.20.000
Extracts of glands and other organs or of their secretions
n.a
n.a
6506
26430
n.a
n.a
3001.90.110
Heparin in blocks
n.a
n.a
n.a
n.a
n.a
n.a
3001.90.190
Heparin in in other form
3001.90.900
Other glands and other organs
3002.10.100
Plasma protein in solution
3002.10.900
Other antisera and other blood fractions
3002.20.110
Pertussis vaccines
3002.20.190
Other bacterial vaccine for human medicine
3002.20.200
Campak vaccine; meningitis vaccine
3160
8451
n.a
n.a
n.a
n.a
13356
145849
n.a
n.a
n.a
n.a
338931
n.a
n.a
1430
355466
4160
29946
1475796
12344
1763310
53598
3E+06
1258
222000
n.a
n.a
14730
1E+07
3610
158645
n.a
n.a
n.a
n.a
213816
5269854
n.a
n.a
n.a
n.a
3002.20.900
Other vaccine for human medicine
34853
2133374
725
117245
28529
3E+06
3002.30.000
Vaccine for veterinary medicine
40399
551662
61096
541555
167570
968828
- 31 -
3002.90.000
Other human or animal blood for therapeutic
38273
1187763
36239
635628
33383
1E+06
3003.10.000
Medicaments containing penicilins or derivatives not measured in dosage
20472
46943
3128
9655
n.a
n.a
3003.20.000
Medicaments containing other anti biotics
48135
2799112
n.a
n.a
1985
24269
3003.31.000
Medicaments containing insulin consist of 2 or more constituent
6384
174505
n.a
n.a
n.a
n.a
3003.39.000
Other Medicaments containing hormons
489008
3732885
66465
921443
45734
1E+06
3003.40.100
Veterinary medicaments containing alkaloids
3990
30409
n.a
n.a
n.a
n.a
3003.40.210
Alkaloid for human medicaments containing narcotics
1439
8260
n.a
n.a
n.a
n.a
3003.40.290
4241
30547
n.a
n.a
n.a
n.a
3003.90.100
Other human medicaments containiong narcotics

Prep 2 or more mix prod. Of veg. Animal or mineral subs in measured
dosis
1260
22119
n.a
n.a
n.a
n.a
3003.90.910
Veterinary medicaments
424
33439
n.a
n.a
n.a
n.a
3003.90.923
Other human medicaments containing phsychotropics
594
42559
n.a
n.a
n.a
n.a
3003.90.929
Other human medicaments
3004.10.000
Medicaments containing penicilins or derivatives measured in dosage
1584155
1.3E+07
n.a
n.a
n.a
n.a
313458
1.1E+07
39768
3546018
47245
2E+06
n.a
3004.20.100
Veterinary medicaments containing other antibiotics in measured doses
9338
476954
20436
644432
n.a
3004.20.200
Human medicaments containiong other antibiotics in measured doses
140186
3539582
n.a
n.a
n.a
n.a
3004.31.000
Medicaments containing insulin consist mixed or unmixed constituen
664
13903
990
79002
n.a
n.a
3004.32.000
Medicaments containing adrenal cortex hormons
3004.39.000
Other medicaments containing hormons but not with antibiotics
3370
197611
n.a
n.a
n.a
n.a
1072866
2.4E+07
n.a
n.a
126725
2E+07
255
16227
n.a
n.a
n.a
n.a
n.a
n.a
n.a
n.a
n.a
n.a
4713
158129
n.a
n.a
n.a
n.a
244467
3639487
25731
489844
312324
6E+06
126274
637328
n.a
n.a
n.a
n.a
60751
486171
n.a
n.a
n.a
n.a
3004.40.100
Veterinary medicaments containing alkoholoid in measured doses
3004.40.210
Alkaloid for human medicaments containing narcotics for retail sales
3004.40.290
Other alkaloides for human medicaments for retail sale
3004.50.000
3004.90.100
other medicaments containing vitamin or other products

Prep 2 or more mix prod. Of veg. Animal or mineral subs not list in
Indonesia
3004.90.910
Veterinary medicaments for retail sales
3004.90.922
Other human medcaments containing phsychrotropics
5486676
3.3E+07
n.a
n.a
n.a
n.a
3004.90.929
Other human medcaments containing sulphinamides
5486676
3.3E+07
n.a
n.a
n.a
n.a
E. Standards and technical regulations

The Indonesian National Drug Policy was established in 1983 with the objectives of ensuring
availability of essential drugs through equitable distribution, ensuring drugs efficacy and safety, as
well as promoting the rational use of drugs.
1.
Drug Regulatory Authority
At the central level, the regulatory authority for pharmaceuticals is the Directorate General of Drug
and Food Control (DG DFC). Its main functions are to formulate policies and programs on drugs; to
control production, distribution and utilization of drugs; and to supervise and control the supply of
drugs for the public sector. In the private sector, DG DFC performs drugs registration, provides
licenses for drugs imports and exports, controls drug promotion, monitors and supervises for
implementation of Good
Manufacturing Practices (GMP), assures the quality of drugs before and after in the market and
monitors distribution of drugs. The Directorate General of Community Health Services coordinates
with DG DFC to develop Standard Treatment Guidelines for primary health care.
- 32 -
2.
Selection
The Indonesia Essential Drug List (EDL) is revised every three years. The revisions are a result of
meetings and consultations organized by the Committee for Essential Drugs List Formulation and
Revision appointed by the Minister of Health. The Indonesia EDL is stratified to reflect requirements
at different levels such as hospital, primary health center and village drug depots, while the WHO
EDL is not stratified into different levels of health care. Compared to WHO EDL, the Indonesia EDL
has fewer items.
Public hospitals and community health centers are obliged to use drugs on National Essential Drug
List (NEDL). Use of drugs outside of the NEDL is not allowed in community health centers but is
allowed in hospitals. This deviation must be approved by the hospital director and reported to the
National Committee on the NEDL. Due to budget limitation the total value of these deviations should
not be more than 25% by value. The private sector is not obliged to follow the NEDL. However, some
private hospitals have started using the NEDL as a reference for developing their own hospital
formulary.
3.
Production and quality assurance
There are 272 registered pharmaceutical companies consisting of 35 multinational, 237 national and
four government companies. In terms of value, 95% of all drugs for public and private sectors are
produced locally. The national private pharmaceutical companies produce almost all drugs including
vaccines on the NEDL. Drugs for the public sector and generic drugs are mainly produced by
government-owned pharmaceutical companies.
The National Quality Control Laboratory (QC Lab) and the 27 provincial QC Lab were developed
with the assistance of WHO. The government controls for quality by taking samples from the field to
be analyzed in the quality control laboratory. Implementation of Good Manufacturing Practices
(GMP) in pharmaceutical factories was started in 1971.
F. Trade and industry policy environment

1.
Overview
In 1992, the ASEAN Economic Ministers formed the ASEAN Consultative Committee for Standards
and Quality (ACCSQ), which set up a Pharmaceuticals Product Working Group (P-PWG) in 1999,
with Malaysia as the lead country. The objective of this group of experts is to harmonise differences
of regulations in the ASEAN member states, and to develop harmonised guidelines with the aim of
arriving at a Mutual Recognition Agreement (MRA).
The National Agency of Drug and Food Control (Jakarta, Indonesia) confirms that Indonesia observes
patents for a period of 20 years, and is very keen to be regarded as a reliable partner in the World
Trade Organization (WTO, the international organisation dealing with rules of trade between nations)
and agreements like TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights).
- 33 -

2.
Major agreements
(a)
TRIPS
Indonesia is of the view that TRIPS will delay the introduction of generics, increase prices and reduce
access to medicines for the majority of patients in developing countries, TRIPS will on the other hand
increase foreign direct investment as well as technology transfer, and enhance local innovation. In
order to compensate the protection of innovative medicines, testing and regulatory approval of
generics will be allowed before patent expires. Also parallel importation without the consent of the
patent holder, and Compulsory License (marketing authorisation granted without permission of the
patent holder) is allowed in defined cases.
(b)
ASEAN Mutual Recognition Agreements
AFTA aims to eliminate all tariff rates, non-tariff barriers and technical barriers to trade. In order to
reach this challenging goal, product standards need to be harmonised through alignment with existing
international standards e.g. ICH, and by implementing Mutual Recognition Agreements (MRAs). The
Bureau of Trade, Industry and Services, ASEAN Secretariat, Jakarta, outlines that MRAs help to
avoid duplication of testing, reduce costs for industry and encourage innovation.
In 2000, the ACCSQ signed a Memorandum of Consultation with the USA. There is also an EU
Regional Cooperation Programme on Standards, Quality, and Conformity Assessment to be
implemented in the ASEAN region.
For the pharmaceutical industry, however, the most important ASEAN MRA is the Agreement on
Common Technical Requirements (ACTR) and subsequently on a Common Technical Dossier
(ACTD) in this region. The plan is to agree on the ASEAN CTR first, followed by an agreement on
the ASEAN CTD.
(c)
ASEAN Common Technical Requirements (ACTR)
In a first phase, the experts compared existing registration requirements, and developed the ASEAN
Common Technical Requirements (ACTR). The workload was split between the countries as follows:
ACTR Administrative Data: Malaysia
ACTR Quality: Indonesia
ACTR Safety: The Philippines
ACTR Efficacy: Thailand
3.
Customs procedures in general
(a)
Structure of the tariff schedule
Indonesia applies a nine-digit tariff nomenclature based on the Harmonized System. The tariff
schedule has six columns showing the import duty rates as well as the rates of additional import
duties, value added tax, sales tax on luxury goods, and import trade procedure regulations.
The last column is reserved to accommodate other provisions, which are not yet accommodated in the
previous column.
- 34 -

(i)
Tariff rates
Import are classified in four broad groups for tariff assessment purposes, with the highest
duties applying to the least essential items:
Group A for most essential items such as, rice, flour, certain iron and steel products, certain
organic chemicals and pharmaceuticals, cotton, medicine, some fertilizers and insecticides,
agricultural and industrial machinery and equipment, and some raw materials.
Group B includes essential items, i.e. materials and spare parts for industry.
Group C for less essential items, and
Group D covers luxury goods, some consumer goods; and in the case of manufactured goods
and machinery, finished goods and those that lessen the need for manpower are subject to
higher rates of duty.
In general, tariffs are high on goods less essential for economic development and basic
consumer needs and goods competing with locally produced items.
(ii)
MFN
MFN duty rates range from 5% to 30% based on the CIF value. All food items are dutiable at
a maximum of 5%. Motor vehicles are dutiable at up to 80%, with automotive parts dutiable
at 15%. Distilled spirits and certain basic chemicals are dutiable at 170%. In the agricultural
sector, some products such as wheat, rice flour, yellow soybeans, cane sugar, coconut and
palm oil are zero-rated.
(iii)
Bound rates
Bound rates are set on about 38.4% on all goods, 47.3% on agricultural goods, and 36.8% on
manufacturing goods.
(iv)
Temporary reduced duties
Duty reductions and suspensions are granted to investment import destined to selected internal
market oriented industries and certain service activities. Goods imported for use in the
manufacture of export products are exempt from import duties, value-added taxes, and sales
taxes, as are goods imported for use in foreign-funded government projects. The main
exemptions or reductions cover the importation of capital goods and raw materials used in the
production processes of projects approved by BKPM. There are also schemes of drawback
and exemption, which provide for the importation of inputs free of tariffs and licensing
requirements. Also, the Finance Ministry may grant additional tariff exemptions to promote
certain industries, e.g. certain cable makers and producers of electronic products for imports of
polyethylene.
On January 2001, the government has decided to reduce import tariffs between zero and 25 %
on over 1,000 product items. The import tariff reduction affects a wide range of products
including paint, varnish, cosmetics, woven cotton clothes, gold (not coin), platinum, cooking
wares, screws, gloves, bed covers, toys, synthetic flowers, watches, electrical devices and
many other products.
- 35 -
(v)
Preferential duties under trade agreements
As the vast majority of Indonesia imports are subject to MFN rates, Indonesia tariff
preferences are essentially confined to ASEAN partners. Duty rates under the Common
Effective Preferential Tariff (CEPT) scheme are only valid for imported goods bearing
certificates of origin from ASEAN countries except goods valued under US$ 200 FOB. The
preferences relate to the implementation of the AFTA scheme, since the vast majority of
Indonesian imports are subject to MFN rates.
Indonesia is a member of the Association of Southeast Asian Nations (ASEAN) together
with Brunei, Cambodia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand and
Vietnam. ASEAN aimed at promoting economic, social, cultural and scientific ties, as well as
trade and monetary policies. Other areas of cooperation among ASEAN members include
harmonization of standards, reciprocal recognition of tests and certification of products.
In 1992, ASEAN members called for the formation of an ASEAN Free Trade Area. In
December 1998 members agreed to implement the AFTA by 1 of January 2002. In this
regard, the six original founding members of ASEAN, Brunei Darussalam, Indonesia,
Malaysia, Philippines, Singapore, and Thailand, would advance the implementation of AFTA
from 2003 to 2002. In addition, a minimum of 85% of the tariff lines in the Inclusion List of
these nations would be reduced to 0-5% by 2000 and 90% by 2001. Vietnam which joined
ASEAN in 1995 would implement its tariff reductions to 0-5% by 2003; Laos and Myanmar
which joined the group in 1997, will complete the reductions by 2005. Cambodia joined
ASEAN in 1999 and will complete the tariff reductions by 2010. No common external tariff is
planned; tariff rates on imports from non-Asean countries will continue to be determined
individually.
Consequently, since 1 of January 2003, the ASEAN countries have announced the abolishment
of tariffs on 60 % of traded goods and the introduction of a 5% on import tariffs within its six
original members, i.e. Indonesia, Brunei, Malaysia, the Philippines, Singapore and Thailand.
Products affected essentially by this measure are electronic products, machinery items and
petrochemicals. And good excluded from the tariff-reduction agreement are goods of key
industries in some of the member countries; for example, Indonesia and the Philippines will
delay the 5% cap on sugar and petroleum, and Malaysia will shelve the cap on car imports,
until 2005. As for Cambodia, Myanmar, Lao People's Democratic Republic and Vietnam, the
four ASEAN's latecomers, will introduce the 5 % tariff cap only in 2010.
Indonesia is also a member of the Asia Pacific Economic Cooperation (APEC) along with
Australia, Brunei, Canada, Chile, China, Chinese Taipei, Hong Kong, Japan, Rep. of Korea,
Malaysia, Mexico, New Zealand, Papua New Guinea, Peru, the Philippines, Russia, Singapore,
Thailand, the United States, and Vietnam. APEC is a multilateral forum formed in 1989 so
that Asian and Pacific economies can promote economic cooperation and mutual assistance in
developing key economic sectors, including trade and investment. On 15 of November 1994,
member countries agreed to implement open and free trade among themselves by 2020, with
advanced industrialized nations realizing the trade liberalization goal by 2010. At their 1997
meeting in Vancouver, APEC leaders agreed on Voluntary Sectoral Liberalization (EVSL) to
take place in 15 sectors and the tariff elements of nine sectors were identified under the
accelerated tariff liberalization (ATL) package i.e. chemicals, energy, environment, fish and
fish products, forest products, gems and jewellery, medical equipment and instruments, and
- 36 -

toys, as well as a mutual recognition agreement concerning telecommunications. The ATL
initiative aimed to achieve a zero target for almost all the sectors by 2005.
(b)
Fees (Customs Duties and Tariff Nomenclature)
Customs duties and import-related taxes currently applicable are:
Import duties which vary from 0% to 170% rates;
Value Added Tax (VAT) which is 10% except for certain goods (e.g. unprocessed and/or natural
products);
Sales Tax On Luxury Goods with rates vary from 10% - 75%;
Income Tax, which is 2.5% for Registered Importers and 7.5% for Unregistered Importers;
Anti-dumping and countervailing duties, if any.
The above taxes are on CIF (Cost, Insurance and Freight) basis. Payment of the taxes can be done
through foreign exchange bank or directly through Customs Office during office hours before
submission of customs declaration. At Customs Offices where EDI system is fully implemented,
payment can be done through electronic transfer.
(c)
Valuation
The customs value of imported goods is the transaction value which is the price actually paid or
payable for the goods and may be adjusted in accordance with the provisions of article VIII of the
agreement on Implementation of Article VII GATT 1994 (WTO Valuation Agreement). The
Indonesian Customs has implemented the agreement fully since 1 January 2000. The Agreement
provides that transaction value between both the buyer and seller can be accepted as long as both sides
are not related, or where the buyer and seller are related, that the transaction value is acceptable as
long as it does not influence the price. Several basic principals used by the customs to determine
whether or not the relationship influence the prices are as follows:
Where the price paid is based on normal transaction in trade of the industry;
The import price is relatively the same as the selling price to the unrelated party; or
The import price has already included production cost and profit.
(d)
Inspection
Indonesian Customs has been using EDI (Electronic Data Processing) to process customs declarations
submitted by the importers. The system is done especially in major ports such as Tanjung Priok
Seaports and Soekarno-Hatta Airport branch offices. In other offices, it may be done manually or
using diskettes (semi-computerized).
Customs examinations, consisting of document verification and/or physical inspection, are applied for
imported goods based on very selective basis. Physical inspections shall be focused particularly on
high-risk imported goods. High-risk means that physical inspection shall be applied only based on
customs intelligence information or by random sampling automatically determined by computer. The
imported goods that should be physically examined are passed through red channel which are not
more than 10% of total import, while the others are passed through green channel.
- 37 -

Indonesian Customs has set up a standard time frame for each step of cargo clearance. For example,
red channel or green channel decisions must be done within 4 hours since the import declaration was
submitted, and when the physical examination is needed, it must be ready to be conducted within 12
hours and finished not more than 40 hours. Also, when there is no indication of cheating, the cargo
can be released before the document clearance for importers own good.
Any person/importer who is not satisfied with the decision made by the Customs regarding tariff
classification and/or valuation, may file a written objection to the Director General of Customs and
Excise within 30 days of the date of the assessment by depositing a security promise at the amount of
the taxes due. The Director General should make the decision on the objection within 60 days period.
If the period has passed without any decision made, the objection shall be deemed accepted and the
security must be returned.
If the person/importer is still unsatisfied with the decision made by the Director General regarding
classification and valuation, he or she still has the chance to file written appeal to the Board of Tax
Dispute Settlement within 60 days after the taxes due have been paid.
(e)
Activities/measures
The Indonesian Customs Authority has taken all necessary steps to better facilitate export and import.
It also has been working diligently to transform itself from merely an agent of revenue collection and
law enforcement to amore trade facilitator. To meet this challenge, some measures have been taken to
improve customs services. These include:
In April 1, 1995, Indonesia enacted a new Customs Law No 10/1995 which has come into effect
since April 1, 1997. The Law accommodates some basic elements to provide, among others, better
trade facilitation.
Since April 1, 1997, Indonesia has provided an Advance Tariff Classification facility. The facility
enables traders and importers to have a written information on tariff classification and import duty
rate of goods, which will be imported prior to the lodgment of customs declaration.
In April 1, 1998, Indonesia has fully applied the Electronic Data Interchange (EDI) system in
some of its main customs service officers.
The Tax Appeal Court has been operated since April 1998.
Indonesia has fully implemented WTO Valuation Agreement since January 1, 2000 by providing
necessary procedure on customs valuation.
Indonesia will ratify the Kyoto Convention on he simplification and harmonization of customs
procedures, once the Convention is completely revised.
Indonesia is in the process of accession to the ATA Convention.
Indonesia has applied Harmonized System Convention as a basic nomenclature for its customs
purposes.
Indonesia is developing Harmonized Trade Data Element in accordance with the implementation
of UN/EDIFACT.
Indonesia has taken several customs related actions to implement the TRIPs Agreement by the
year 2000.
- 38 -
Indonesia also provides necessary information (e.g. brochures) in strategic locations such as
airports and seaports, and has introduced the Indonesian Customs Web Site
(http://www.beacukai.go.id) and the Indonesian APEC Customs contact point
(soegito@innocent.com).
Indonesia has further improved the implementation of Risk Management Approach in order to
enhance the expeditious flow of goods.
In accordance with the main principles of WCO Guidelines on Express Consignment Clearance,
Indonesia implements a specific customs clearance procedure called Rush Handling.
By using Post Clearance Audit Methods, Indonesian Customs Administration intensifies its efforts
on combating fraud, particularly in customs valuation area.
In achieving the Bogor goal, Indonesia has been active in the work of the Sub Committee on Customs
Procedures. Additionally Indonesia has prepared to work together with all member economies to
better simplify and harmonize customs procedures in the region by fully taking into consideration the
principles of Facilitation, Accountability, Consistency, Transparency, and Simplification.
4.
Import restriction
(a)
Import licenses
Import into Indonesia maybe conducted only by companies having import license procured from the
Ministry of Industry and Trade. To import pharmaceutical products, a company must have import
license from the Ministry of Industry and Trade and be registered as a pharmaceutical wholesaler with
a permit from the Ministry of Health.
(b)
Quotas
Officially, there are no quotas or restrictions in importing pharmaceutical products. Under an

emergency situation, however, the Ministry of Health has allocated around US$ 180 million to import
pharmaceutical ingredients by an appointed importer. The ingredients are processed into generic
medicines for sales to the public and government institutions through usual channels of distribution.
(c)
Bans
There are no special arrangements to prohibit import of pharmaceutical products from any country.
Indonesia follows the general rules if importation which are WTO compliant.
Import licenses are extended to any company incorporated in Indonesia, which can be a limited
liability company (PT), a state owned limited liability company (Persero) or a cooperative.
Summing up, a company wishing to import pharmaceutical products should have the following:
A permit as a pharmaceutical wholesaler or a pharmaceutical manufacturer from the Ministry of

Health
An import license from the Ministry of Industry and Trade
Adequate room and equipment to store serums and vaccines
- 39 -
Laboratory facilities particularly to test and evaluate serums and vaccines. In the absence of the
same, the company concerned should have an arrangement with a laboratory appointed by the
Ministry of Health to test serums and vaccines
An import license is non-transferrable.

5.
Investment requirements in general
(a)
General policy
In order to drive investment, general policies of Indonesian Government among others are:
Government Regulation No.20/1994 and Presidential Decree No.31/95 provide that foreign
investors are allowed to acquire 100% shares of the company; and pharmaceutical sector is open
for foreign direct investment. A joint venture is only required in eight investment sectors vital to
the public interest, such as the operation of harbors, telecommunication, power generator, shipping
lines, potable water, public railways and nuclear power generator;
The minimum capital requirement for foreign investment has been eliminated;
Ministry of Finance Decree No.297/1997 jo.No.545/1997, 546/1997, and 135/2000 provide

exemption or deduction of import duty for production machines, equipment and raw materials for
new investment. It is also apply to industries which restructuring their production capabilities
(such as diversify and improve the quality of the products).
Investment application, including approval procedure, has been substantially simplified. Foreign
investments application with a value of up to US$ 100 million (which formerly needed the
Presidents approval) is now only subject to the approval or the Minister of Investment/Chairman
of the Investment Coordinating Board. The Investment Coordinating Board (BKPM) is now also
making the necessary preparations to grant more authority to Local Government Authority to issue
investment licenses.
Tax incentive to the investor for 22 categories of manufacturing activities. The basic period of
enjoying the tax incentive is three years for Java and Bali. Beyond this period the incentive can
still be extended up to 12 years maximum if certain requirements are met.
(b)
Equity restrictions/requirements
Government Regulation No.20/1994 provides that foreign investors are allowed to acquire 100%
shares of the company established in Indonesia. Therefore, there is no equity restriction implemented
in connection with investment regulation in Indonesia.
(c)
Profit repatriation requirements
Not applicable.
(d)
Foreign exchange balancing requirements
Not applicable.
- 40 -
G. Export policies and incentives

1.
Export controls
Like Indonesia's import tariff regime, export controls are in a state of rapid change as the government
works to implement reforms associated with the IMF program. Many of the restrictions and taxes
placed on exports affect agricultural products, including major cash crops like rubber, palm oil,
coffee, and copra. Export restrictions and controls are applied by the government to a number of food
commodities, most notably crude palm oil (CPO) which remains subject to a 5 % export tax, in an
effort to ensure adequate domestic availability and stable prices of such products, particularly with the
weak economy in recent years.
2.
Research and development
The Ministry of Finance Decree No.769/1990 provides that Research and Development cost could be
deducted from gross income of the company. This policy is to drive companies to do a R&D activity
in order to improve performance of the company and to invent new technology.
3.
Human resources development
The similar incentive is also applicable to those upgrading the capability of their human resources
through training activities. This is stipulated in the Decree of Ministry of Finance No.770/1990.
4.
Tax incentive
The Government Regulation No.45/1996 provides the tax incentive to an investor for 22 categories of
manufacturing activities. The basic period of enjoying the tax incentive is three years for Java and
Bali. Beyond this period the incentive can be extended up to 12 years maximum if certain
requirements are met.
H. Import practices
In recent years, Indonesia has liberalized its trade regime and taken a number of important steps to
reduce protection. Since 1996, the Indonesian Government has issued a series of deregulation
packages that have reduced overall tariff levels, simplified the tariff structure, removed restrictions,
replaced non-tariff barriers with more transparent tariffs with the aim of encouraging foreign and
domestic private investment.
1.
Trade barriers
Despite the severe economic crisis of the past four years, Indonesia has maintained its policy of steady
long-term tariff liberalization. Indonesia's applied tariff rates range from 5 to 30 %, although bound
rates are, in many cases, much higher. The long-term liberalization policy has been reinforced by
consecutive IMF programs in which Indonesia committed to implement a three-tier tariff structure - 0,
5 or 10 % - on all imported products except motor vehicles and alcoholic beverages. Indonesia also
committed to eliminate all non-tariff barriers, except those for health or safety reasons, by the end of
2001.
- 41 -
Indonesia has liberalized its distribution system, including ending some restrictions on trade in the
domestic market. For example, restrictive marketing arrangements for cement, paper, cloves, other
spices, and plywood were eliminated in February 1998. Indonesia opened its wholesale and largescale retail trade to foreign investment, lifting most restrictions in March 1998. Some retail sectors are
still reserved for small-scale enterprises under another 1998 decree. Large and medium scale
enterprises that wish to invest in these sectors must enter into a partnership agreement with a smallscale enterprise although this may not require a joint venture or partial share ownership arrangement
2.
Customs valuation
Since April 1997, the Customs Directorate of the Ministry of Finance has operated a post-entry audit
system, which relies primarily on verification and auditing rather than inspection to monitor
compliance. A paper-less electronic data interchange system that links importers, banks, and customs
was also introduced and is slowly being adopted. Indonesia is in compliance with the WTO Customs
Valuation Agreement but U.S. companies operating in Indonesia have reported problems with
Customs procedures and valuations made by Indonesian Customs. The U.S. government continues to
monitor the situation.
3.
Import licenses and restrictions
According to the Directorate General of Customs and Excise the following goods are still subject to
import restrictions, licensing and/or prohibition: narcotics, psychotropics, explosive materials, firearms and ammunition, fireworks, certain books and printed materials, audio and /or visual recording
media, telecommunications equipment, color photocopying equipment and parts and equipment
thereof, endangered wild fauna and flora and parts thereof, certain species of fish, medicines,
unregistered food and beverages at the Department of Health, dangerous materials, pesticides, ozonedepleting substances and goods containing ozone depleting substances, wastes, culturally valuable
goods, and other items. In 2000, the Government of Indonesia banned the import of U.S. chicken
parts, which has been the basis of a trade dispute between the two countries.
Import restrictions and special licensing requirements have been or still are imposed on other goods,
such as alcoholic beverages, hand tools, artificial sweeteners, engines and pumps, tractors, rice and
lube oil, although such requirements may not be consistently applied. The government controls the
import of videotapes, laser discs and other entertainment products for both exhibition and private use.
Such goods are subject to review by a censor board.
4.
Import documentation requirements
The government requires the following for most imports: pro-forma invoice; commercial invoice;
certificate of origin; bill of lading; insurance certificate; special certificates.
According to the Indonesian Customs Law that came into effect in April 1997, importers are now
required to notify the Customs Office in the first stage by submitting the import documents on a
standard form computer diskette. Customs Inspections of imported goods may be made after they are
imported in the importer's warehouse. Typically, the Indonesian importer takes care of the process.
- 42 -
5.
Free trade zones and warehouses/import provisions/temporary entry
The government encourages foreign investors who export to locate in bonded or export processing
zones (EPZ). There are a number of EPZs in Indonesia, the most well-known being Batam Island,
located 20 km. south of Singapore. Indonesia also has several bonded zones or areas that are
designated as entree ports for export destined production (EPTE). Companies are encouraged to locate
in bonded zones or industrial estates whenever possible. Other free trade zones include a facility near
Tanjung Priok, Jakarta's main port, and a bonded warehouse in Cakung, also near Jakarta.
There is a duty drawback facility (BAPEKSTA) for exports located outside the zones. Producers
located within the bonded areas are allowed to sell up to 15% of their product into the local market.
Foreign and domestic investors wishing to establish projects in a bonded area must apply to the
National Investment Coordinating.
6.
Labeling and marketing requirements
Food labeling regulations requiring labels in the Indonesian language and expiration date (rather than
the standard "best used by" date) are in place but are not being enforced. A product registration
regulation is also in place that requires detailed product processing information so as to approach
proprietary information. The registration procedure can also be quite lengthy and expensive.
Indonesian importers and US exporters have expressed concern that these regulations could act as
non-tariff barriers to imports of packaged food products.
The market for foreign pharmaceuticals has been open since the October 1993 Deregulation
Package. Previously Indonesia limited pharmaceutical imports to those that incorporated high
technology and were the product of their own company's research. The 1993 package also relaxed the
registration requirements for pharmaceuticals approved in other countries. Foreign pharmaceutical
companies report ongoing problems obtaining timely registration of new products from the Ministry
of Health. New regulations issued in July 2000 have helped reduce some of the backlog in new
registrations.
7.
Membership in Free Trade Agreements
As a member of the Association of Southeast Asian Nations (ASEAN), Indonesia is party to the
ASEAN Free Trade Agreement (AFTA). Through AFTA, ASEAN members are phasing in a
Common Effective Preferential Tariff (CEPT) scheme, which will be completed for most traded
goods in 2003.
I. Distribution system
1.
Overview
To get a license for a new product, a pharmaceutical company must apply to the Indonesian
Department of Health. The procedure takes two months to a year, depending on the product.
Companies who apply for a license eventually get one. The main problem is the government
bureaucracy, which is sometimes very inefficient.
- 43 -

Sometimes "facilitating fees" may have to be paid to officials to get the license easier and on time.
This practice is common in Indonesia, although, of course, it is illegal. Foreign companies with U.S.
parents face the special jeopardy of the (US) Foreign Corrupt Practices Act in this context.
In Indonesia, factories are not allowed to sell their products directly to the consumers or retailers; they
must go through wholesalers. There are two major types of retail establishments that distribute
pharmaceutical products to the public. Apotik is the Indonesian term for pharmacy, apothecary or
dispensary. Apotiks sell prescription drugs and a small number of OTC drugs. Most apotiks are agents
of particular pharmaceutical firms. They are highly regulated by the government, and must be
managed by certified pharmacists. Toko obats, meaning medicine shops, sell OTC drugs, along with
some fakes and illegally imported drugs from the gray market. The products sold by toko obats are
usually cheaper than those sold by apotiks.
The distribution pattern and the state of the pharmaceutical industry in general is characterized by two
distinct government policies that are partially conflicting. On one hand, the government attempts to
maximize national capabilities including ownership of pharmaceutical production and distribution,
which enable the country to be "self-sufficient" in providing drugs to the people at minimum cost. On
the other hand, the Indonesian government, like many others, has been concerned with the safety of
drugs offered. Thus, in order to help the "local" pharmaceutical industry to grow and, at the same
time, control the quality of drugs in the market, Indonesia banned imports of most medicinal drugs in
1976. Imports accounted for only 2% of the country's consumption of pharmaceuticals by the end of
the 1980s. Local producers, therefore, do not have to fear competition from imported products.
However, many importers have been known to resort to illegal operations since the government ban
on imports. Some wholesale companies, which previously operated as importers, have turned to illicit
trade, such as smuggling and/or producing unauthorized imitations in order to survive.
Products smuggled from Taiwan, Singapore or Hong Kong are not all fakes, but name brand products
that are cheaper to import because production costs in those countries are lower. Most of the products
sold via the gray market are nonregulated OTC drugs, which are sold by toko obats and wholesalers.
Apotiks and hospitals do not buy gray market products. The government has taken some measures
against companies found engaged in illegal activities. On the other hand, the government has
encouraged previous importers to operate as distributors.
Although Indonesia has officially established a system of Patent Rights, there are still lots of fake
products in the pharmaceutical market. Some "look alike" brands are still legally permitted, especially
those produced by local companies. These products are cheaper than the "originals." There are also
some imported fakes from Taiwan and Hong Kong. Most of them are cheaper, and sold by toko obats
that have to comply with few regulations in this regard. By contrast, most apotiks do not sell fakes,
because there are regulations against selling imitation products.
Apotiks caught violating these regulations may be fined or even closed by the government. Producers
are largely required to leave the promotion and distribution tasks to wholesale companies. Increasing
requirements for wholesale companies to serve as both distributors and promotional agents has made
the distribution business more interesting. It is financially attractive because of the relatively low cost,
since the pharmaceutical producers pay most of the costs. As the major link between the
pharmaceutical industry and the market, the business is relatively safe, due to the continuing demand
for drugs. A growing number of companies have been attracted into this line of business.
- 44 -

According to one estimate, 50% of the pharmaceuticals produced in Indonesia are distributed through
apotiks, 30% are distributed to toko obats and the remaining 20% are distributed directly by practicing
physicians and hospitals.
Therefore, apotiks play an important role in Indonesia's pharmaceutical industry. There are some
9,216 (2005) apotiks registered in the country located all over the country, mostly on Java. There are
2,300 apotiks on around Jakarta (JABODETABEK), which represents 25% of the total number in the
country. The number of apotiks increased by 300% compared with 2003. Java remained on top with
68%.
The role of toko obats is also important. Toko obats sell pharmaceuticals at relatively cheaper prices,
often 10% to 20% less than apotiks. Many people therefore, buy from toko obats rather than from
apotiks. The number of drugstores operating in Indonesia has also increased. Many of them are not
properly registered, although the government has tightened licensing procedures. There exist
approximately 6,737 (2005) registered drugstores, compared to 1,639 in 2003. As is the case with
wholesale companies and apotiks, Java has the largest number of toko obats. There are more 1,012
toko obats on Java, accounting for 50.5% of the total number in the country. Toko obats, however, are
spread more evenly than apotiks. Effectively, toko obats serve in the role of apotiks in small towns
and rural areas.
In addition to OTC drugs, stronger drugs are also available at the toko obats outside metropolitan
areas. In these locations, toko obats act like apotiks, and, on occasion, strong drugs are even sold by
cigarette retailers on the street (see exhibit below).
- 45 -
2.
Wholesale traders by provinces
Two new decentralization laws, which have recently been enacted: Law no. 22/1999 that deals with
provincial and local governments, and Law no. 25/1999 on fiscal equalization between central and
local governmentshave brought fundamental changes in the basic roles and responsibilities of the
central, provincial and district governments. Provincial and district governments now hold more
important role in procurement of health services including the public supply of medicines. Therefore,
there is an increasing number of pharmaceutical distributors throughout the regions of Indonesia. In
1997, there were only 1,631 wholesale distributors, while the number has increased to 2,393 in 2005
and to 2,478 in 2003.
Pharmaceutical Wholesaler Traders by Province 2007
Province
Jakarta
Banten
East Java
West Java
Central Java
North Sumatra
South Sumatra
Bali
West Sumatra
Riau
Lampung
East Kalimantan
South Kalimantan
East Nusa Tenggara
West Kalimantan
NAD
Yogyakarta
Papua
Jambi
Maluku
West Nusa Tenggara
Bengkulu
Central Kalimantan
Nort Sulawesi & Gorontalo
Centre Sulawesi
Southeast Sulawesi
South Sulawesi
Indonesia
Source: Almanak GP Farmasi Indonesia, 2007
2007
392
20
250
252
252
140
100
80
71
68
62
37
55
24
66
62
54
28
30
30
46
10
6
48
26
6
98
192
- 46 -
J. Pharmaceutical sales promotion and pricing

Pharmaceutical factories advertise their non-ethical products through the media such as newspapers,
magazines, radio and billboards. Ethical products are advertised through medical and pharmaceutical
magazines, such as the Index of Indonesia's Medical Services (IIMS), Informasi Spesialis Obat
(Indonesia) (ISO), and especially through promotional seminars. Some producers continue to hire
"detailers" pharmaceutical salespeople) to promote their products directly to practicing physicians.
Such detailing is not always effective, however, because most MDs do not like to meet detailers in
person. Instead, doctors tell their nurses to pick up the samples. Then the doctors contact the detailer
later by phone.
The government health authorities also discourage the use of detailers because they are considered to
be "disturbing the established order." Detailers are no longer allowed to go into hospitals, especially
government hospitals. Consequently, most companies now conduct seminars and workshops to
introduce new products, rather than use detailers. At these seminars, companies present papers and lab
results in conjunction with marketing their products, as is the practice in industrialized countries.
Also, as in the developed countries, manufacturers promote products containing the same active
ingredients under different names and labels, in order to segment the market. Promotion costs are high
and constitute an important factor in price calculations. Some estimates in the industry point that
promotional costs account for up to 30% of the price.
The long distribution line is also a factor in pricing. Under the current system in Indonesia,
pharmaceutical factories distribute their products through a wholesaler in order to service apotiks,
toko obats and hospitals.
1.
Pricing pharmaceutical products
According to a regulation set by Indonesia's Food and Drug Supervision Directorate General, an
apotik (dispensary) is to sell its product at a price 1.425 times the buying (net) price (see the section,
Distribution System of Pharmaceutical Products in Indonesia for a description of retail establishments
distributing pharmaceuticals to the public). A description of the price calculation system used can be
summarized as follows.
- 47 -

Pricing Pharmaceutical Products
1
CIF (raw) price

Import duty
Value added tax (10 %)
Handling cost
Land cost
2
Factory processing cost
Processing cost
Auxilary material cost
Packing
Marketing incl. advertising
3
Production cost (1+2)
4
Factory profit (circa 30 %)
5
Factory Selling Price
6
Wholesaler's profit (20 %)
7
Dispensary's buying price
Exploitation (10%)
Interest on capital
Risk
Margin dispensary
8
Dispensary's selling price
Source: Various Sources (processed)
100
5
10.5
5
120.5
50
20
15
40
245.5
73.7
319.2
63.8
38.3
421.3
48.9
40.7
577.9
In Indonesia there are only 9,216 apotics (2005) and toko obats to service the country's 238 million
people (2007). Complicating the matter further, most Indonesians live in rural areas, whereas most
apotiks and toko obats are located in cities. Consequently, rural people obtain drugs from governmentrun health centers, called Puskesmas and Pos Yandu. A Puskesmas is a subdistrict public health center
served by two or three "junior" doctors and nurses. It is not well equipped and cannot treat severe
illness, but provides adequate services for general sickness and first aid before patients can be treated
at a hospital. A Pos Yandu is a rural area public service center that functions as a multipurpose service
and firstaid post. Staff typically includes a nurse and several social workers, but no doctor. It also
serves as an information center for government family planning, nutrition and welfare programs.
K. Maritime transport services

1.
Availability
Indonesia is heavily dependent on maritime transport for international as well as for domestic trade.
The development of shipping and port services throughout the country has long been a priority of the
Indonesian government, and mainly influenced by the development of surrounded strategic
environment
Over the years, Indonesias maritime industry has evolved from a very extensive public sector
involvement and restrictive licensing and regulatory regime to a much more liberalized and
decentralized system. Deregulation of the maritime sector started in 1985 and has progressed to the
current stage where it allows foreign shipping lines to call at all ports in the country which are opened
for international trade. In addition, Indonesia has no bilateral/unilateral cargo reservation schemes
except for cabotage and specific government cargoes, and also accords no different treatment for
overseas vessels to access to/use of port facilities.
- 48 -

The above measures reflect the liberalization policy on maritime transport services has created an
extensive network of shipping services provided by a large number of foreign shipping lines and a few
domestic shipping lines, which have supported the countrys growing international trade. This is part
of the entire deregulation program in various economic sectors such as trade in goods, taxation,
finance, investment, monetary and other sectors.
From 1996 to 2000, the number of shipping companies has increased: from 1,156 companies in 1996
to 1,724 companies in 2000. In the same period, the number of national merchant fleet increased from
6,156 units in 1996 to 9,196 units in 2000. The volume of sea trade has also increased by the average
growth of 3% per annum. In 1996, the volume of cargo by sea transport amounted to 365,634,280 tons
compared to 417,287,411 tons in 2000.
2.
Suitability
Indonesias infrastructure is well developed around the population centers on Java, Sumatra, and Bali.
In these areas, there are substantial road and rail connections for both passenger and freight transport.
Outside of the major cities, however, the surface transportation infrastructure is not as advanced.
Because Indonesia is an archipelago, sea transport of raw materials and agricultural goods is
extremely important and well developed. Each of the major islands has at least one significant port
city, and on Java and Sumatra,
The principal ports are Jakarta, Surabaya, Semarang and Cirebon on Java, Belawan-Deli and
Palembang on Sumatra and Ujungpandang in Sulaweisi and Merauke in West New Guinea.
Jakarta Container Port (JCP) is Indonesia's largest container terminal and comprises both Jakarta
International Container Terminal (JICT) and KOJA Terminal. JCP is strategically located in the
industrial heartland of West Java and serves as Indonesia's national hub port. A redevelopment project
of is currently underway which will increase JCP's annual handling capacity to over 3 million TEU.
JCP plans to construct an additional 300 meters of berth with a depth alongside of 14 meters below
chart datum and a further 32 hectares of back up area. The upgrading and expansion of JCP will
further contribute to Indonesia's economic development.
L. Packaging
1.
Indonesias Packaging Industry and Methods of Packaging
In line with the fast growth of the consuming industries like the food and drink industry, the cosmetics
and pharmaceutical industry, the electronic and electrical household appliance industry, the furniture
industry, automotive component industry, building material industry and many other industries using
packaging, Indonesias packaging industry is still quite attractive to investors. This development is in
line with the increasing demand for packaging paper used to pack light and heavy products.
Besides, the packaging industry has also improved in performance prodded by development of the
function of packaging from just packaging proper into means of transmitting information and as
means of promotion at the same time for the product concerned. According to The Capital Investment
Coordinator Board (BKPM), for the last two years (1998 u 1999) five investors joined the paper
packaging industry, with a planned investment of Rp 41.1 billion. During the period of January to
August 1999, four foreign investment projects (PMA) with a total investment of US$ 11.6 million
were implemented.
- 49 -

The above development has turned the packaging industry into a rich business ground for suppliers of
products, from the main raw materials down to auxiliary materials, such as cardboard and kraft paper,
plastic film, plastic sheets, aluminum foils, adhesive, printing ink, etc
Among the six packaging types steel, aluminium foil, paper, board, plastic and jute paper and
board are the leading materials. These materials have a 71% market share, from 51% in the early
1990s. The Indonesian industry is able to service its market in terms of quantity, but despite some
improvement, the quality of some of the products is inadequate. There is increasing pressure for more
environmentally friendly materials to be used for packaging. Paper and board, which are regarded as
far more manageable than plastic and metal, have given rise to an estimated paper and board
consumption in 1996 of 700,000 tonnes. The jute industry is also being revived. This is a direct result
of environmental concerns or "green"campaigns.
Currently, demand for packaging paper materials, both board paper and specific packaging paper, is
mostly supplied by local producers. During the last five years (1994 u 1998), production of the two
material types had increased from 767,000 tons in 1994 to 1.3 million tons, an increase of 15.0% per
year. The largest increase occurred in 1996, from 809,040 tons in 1995 to 1.07 million ton, or a 32.8%
rise from the previous year.
2.
Paper and board
Paper and board demand in Indonesia showed strong growth before 1997. In 1997, consumption
reached 4.2 million tons. Indonesia managed to achieve an increase in paper and board consumption
in 1998 as well. However per capita paper and board consumption was low by world standards, at
5.5/kg/yr in 1998. But paper and board demand was hit hard by the economic slowdown of 1998,
which deepened into sharp recession in 1999. In that year, paper and board sales shrank sharply.
Indonesia's good economic result for 2000 helped to rescue paper and board demand. At the end of
2001, total paper and board demand in the country was still below pre-crisis highs. But the economy
was on track to drive this indicator beyond the pre-crisis peak by 2002.
Indonesias comparative lack of purchasing power has meant that it is not always capable of obtaining
the leading edge machinery, which would make it competitive in the world arena. Indonesia does not
only require machinery, but also training and staff development. Packaging is a labour intensive
industry, so Indonesia will continue to benefit from its abundant supply of inexpensive labour.
The paper and paperboard industry is highly dependant on the pulp and paper industry.
Despite the sluggish growth in the country's overall economic condition, the pulp and paper industry
in Indonesia has enjoyed an average annual growth of eighteen % for the last five years. Moreover,
according to the Indonesian Central Bureau of Statistics, pulp imports were ranked as number seven
among the top ten import commodities in Indonesia in 2000. The total import of pulp products
reached US$ 1.1 billion in 2000, an increase of 65% from 1999 at US$ 647 million.
The industry's growth is supported by the high export volume of paper products to various countries in
the world, as a result of the collapse in the value of Rupiah and low local consumption rates.
According to the Indonesian Pulp and Paper Association (APKI), the national paper consumption was
only 3.9 million metric tons in 2000, although this was a fourteen % increase from 3.4 million metric
tons in 1999.
- 50 -
3.
Corrugated carton boxes (CCB)
Corrugated carton boxes (CCB) are typically multi-layer boards used for folding carton packaging.
CCB is considered as a commodity and is mostly used in consumer and agricultural industries for
packaging purposes. The main raw material of CCB is waste paper produced by the paper industry.
The industry is a capital intensive one that is impacted by the development of technology resulting in
improvements in product design and properties (e.g. strength).
Indonesia is a main consumer and leading of exporter of CCB in the Asia-Pacific region. Indonesian
CCB producers are also leaders in regional CCB production. Indonesia has a competitive advantage in
the industry due to an abundant supply of pulp and paper from its tropical forests, complemented by
its cheap labor costs. Local companies, however, are far behind their global rivals in terms of
technology applied in their business. USA, Japan, Germany, France, Italy, and the UK therefore
account for 50% of the worlds packaging. The carton box has been produced in Indonesia since the
1970s and started to expand enormously in the 1990s caused by the fast growing manufacturing
sector. The industry is also opened to foreign investors and many importers import the products from
other countries (subject to an import duty of 10%).
4.
Producers and capacity
Currently, in Indonesia there are 108 companies engaged in the industry with a total installed capacity
of 1.9 million tons per annum and an average utilization rate of 65%. About 75% of the companies are
small to medium size companies. Most of the producers are located in Java particularly in Jakarta and
its surroundings, driven by market demand from consumer industries also located in the same area.
Besides local production, the country also imports CCB from other countries (in small volume),
mainly from the Philippines and USA. Imported products generally are of higher quality than the local
products and are mostly used for packaging of export commodities.
5.
Raw material availability and vertical integration
Raw materials for CCB are linerboard, medium paper and kraft liner, mostly produced by local paper
mills. Raw materials represent 50% to 70% of the cost of goods sold. Thus, raw material cost
fluctuations remain an inherent risk in the packaging industry, including, the CCB industry. Paper
prices are based on pulp prices and are very cyclical driven by its nature as a commodity product. If
raw material prices increase, packaging companies may experience a margin and profit squeeze due to
the difficulty in passing on the increased production costs to customers in a timely manner.
6.
Competition
The industry now is facing increasing competition from larger producers with the ability of vertical
integration forcing some small to medium size companies to stop production and close their
businesses. Currently, many of the remaining companies are seeking to increase their production
capacity, which might result in excess supply in the next few years.
Competition comes from the mini box industry, which usually have better printing machinery to
produce higher quality products, but with higher prices than CCB products. Competition also comes
from recycled board box producers whose products have been used extensively in the Asia Pacific
region caused by more concerns over environment. However, the recycled board box is not popular in
Indonesia at the moment since the raw material for recycled board box is still imported with 15%
higher cost than CCBs raw material cost.
- 51 -

7.
Plastic and flexible packaging
Plastics usage in Indonesia after the economic recession has experienced only adequate growth. The
consumption of PE (polyethylene), PP (Polypropylene), PS (polystyrene) and PVC (PolyVinyl
Chloride) plastics in 2000 had again reached 1.6 million tons. When the economic crisis hit in 1998,
consumption of plastics decreased by more than 40% from the year before, dropping to 900,000 tons.
The recent recovery in the sector was accelerated by strong demand from food and beverages
industries.
The flexible packaging industry generally using as raw material plastic film like BOPP film, PET
film, PVC film, aluminium foil, CPP film, etc. has up to now been faring quite well. In the prolonged
economic crisis situation most companies in the industrial sector have been struggling to stay in
business by pressing down production cost as much as possible. And the use of flexible packaging has
been found to be one solution. Besides being practical and presenting a nice appearance, the use of
flexible packaging can help lower production cost.
In Indonesia there are now no less than 60 flexible packaging producing companies with a total
capacity of 106,605 tons per year. In 1999 production realization was registered at some 64% of
capacity and in 2000 projected at no less than 70% of capacity. Several companies in this industry,
particularly of the big category, have been able to achieve a real output of above 80%. But there are
also companies with an output rate of under 50% of capacity. In all, the production of this industry in
1999 was valued at Rp 1.3 trillion.
The food industry sector has been the biggest consumer of flexible packaging, with an intake of
66.2% of total consumption in 1999, with the pharmaceutical & cosmetics industry and other sectors
accounting for 33.8% of total consumption. Of the food industry, the biggest flexible packaging users
are the instant noodle industry, the snack industry, biscuit industry and candy industry.
8.
BOPP plastic
BOPP film is a high performance biaxially oriented, specialfilm made from polypropylene. It is
primarly used by the packaging industry in packaging, adhesive tapes, capacitors, textile outwrapping,
lamination, cigarette wrapping and reverse printing.
The consumers of BOPP films vary widely. Cigarettes companies are the largest industrial consumer
of BOPP films, followed by instant noodle producers, biscuit producers and manufacturers of
confectioneries. These companies however do not order directly from the BOPP producers. Instead,
the BOPP films are ordered from companies, which convert the BOPP film into the finished product
from the raw material.
Since its introduction in the 1960s, BOPP has been well applied in the packaging industry. In 1997,
there were 187 companies worldwide engaging in BOPP film production, such as Mobil of USA, ICI
of the UK and Toyobo of Japan, with an output of over 2.5 million tonnes. In Indonesia, there are at
least nine companies that produce BOPP film with total production capacity of 123,000 tons per
annum
- 52 -
9.
Overall packaging remains strong
Indonesia saw a surge of investment activity in packaging during the past decade. Most of the
country's packaging production is destined for domestic consumption. The expansion and
diversification of Indonesia's manufacturing sector has been the main driver behind this strong
demand trend. Demand for corrugating materials was affected by the 1998 economic slide, but the
sector suffered less than other grades of paper and board. Manufacturing growth has also been a key
driver behind the rise in production and consumption of boxboard.
M. Export credit and finance

1.
Brief description of banking system
The Indonesian banking system comprises of Bank Indonesia, as the central bank, state banks, private
banks, foreign banks and joint venture banks, while non-banking financial institutions consist of
leasing, venture capital, factoring and the insurance business. The banking industry has rapidly
developed after the issuance of several regulations aiming at liberalizing the banking sector. Next to
the banking sector the government has privatized the Jakarta Stock Exchange in 1992, which then
became an important source of capital for Indonesian enterprises. The goal was to achieve higher
efficiency in the mobilization and channeling of funds to various investment projects. These reforms
were immediately welcomed by investor giving birth to dozens of new banks that rapidly spread
throughout Indonesia.
When the economic crisis hit Indonesia in 1997, it was the banking sector, which received the hardest
impact arising from the sharp depreciation of the Rupiah. This fluctuation was worsened by the fall of
the construction and property industry causing bad loans to soar and leaving a financial drought within
major players in this industry.
Therefore, Indonesia's banking system has only partially recovered from the crisis, and many banks
remain technically bankrupt or are hamstrung by very low capital reserves. Unprecedented levels of
corporate debt have limited the ability of many private sector firms to obtain trade or project
financing, and the cost of imported capital goods has risen substantially in the wake of the Rupiah's
devaluation. These economic factors coupled with lingering political instability have led to steep
declines in both imports and direct foreign investment, and private capital inflows have remained
strongly negative since 1998.
Banks were at ground zero of the 1997-98 financial crisis. When the smoke cleared, the total number
of banks had declined from 238 pre-crisis to 162 (5 state-owned national banks, 27 state-owned
regional development banks, 120 private banks, and 10 foreign branches, not counting joint-venture
banks and foreign banks' representative offices). The Government of Indonesia (GOI) launched a
massive bank recapitalization program in 1999 that has stabilized the banking sector but is not yet
completed. While the banking sector is no longer in a state of collapse, it has not yet recovered to precrisis levels, and several large state-owned banks continue to lose money.
- 53 -
Banks remain reluctant to make new loans outside of the consumer sector, leaving the interest earned
on bank recapitalization bonds as the prime source of income for many. While local banks are not
expected to return to normal levels of business in the near-term, lending by foreign banks and joint
venture banks has resumed on a modest scale to selected customers, primarily exporters. Corporate
loan restructuring has progressed very slowly, and most Indonesian firms find that obtaining trade and
project financing has become significantly more difficult. Many local companies can neither meet
requirements for new loans nor service their existing bank debt. Letters of credit remain difficult to
come by and can face difficulties in gaining acceptance abroad.
Despite lagging progress on bank and corporate debt restructuring, the Indonesian economy has
shown some signs of recovery. According to the World Bank, the GDP growth stood at 5.5% and
6.20% for the years 2005 and 2006 respectively. Inflation and interest rates have declined
dramatically from their mid-crisis levels, but are showing signs of increasing again. Improved export
earnings have enabled Indonesia to have a positive current account balance.
The GOI (Government of Indonesia) has accumulated foreign exchange reserves above the targets set
in its IMF program. Continued improvement is the indicators will strengthen the overall lending
environment, and if sustained, could lead to increased demand for trade financing in the mid-term as
well as enhanced opportunities for exporters.
2.
Foreign exchange controls affecting trade
Bank Indonesia introduced new foreign exchange regulations in January 2001 that have significantly
cut back the flow of Rupiah to offshore markets. The regulations place limits on the quantity of
Rupiah that onshore banks may transfer to offshore parties without underlying trade or investment
transactions. These limits, currently set at US$ 3 million, apply to both each transaction and to a
bank's cumulative derivative transaction position, including forward sales, swaps, and option
contracts. Despite the new restrictions on offshore transfers of Rupiah, Indonesia has no system of
capital controls and foreign exchange flows freely in and out of the country. No prior permits are
necessary to transfer foreign exchange. Foreign investors have the right to repatriate capital and
profits at the prevailing rate of exchange. The government does not place restrictions on outward
direct investment. Foreign Exchange Law No. 24/1999, which entered into force in April 2000,
requires the reporting of all foreign exchange transactions above US$ 10,000.
3.
General availability of financing
In June 2000 Bank Indonesia (BI) announced a package of regulatory changes designed to encourage
bank lending, including trade financing. These measures include amendments to BI's prudential
regulations concerning the recalculation of capital-asset ratios to permit additional credit expansion. A
second amendment to the prudential regulations extends until May 2001 (or December 2002 for loans
restructured through the Jakarta Initiative) the time limits by which all banks must comply with BI's
legal lending limit (the limit concerns the %age of bank credit which may be allocated to individual
firms). A third BI circular relaxed the requirement that banks liquidate equity positions in a debtor
company after 5 years or when the company achieves net profits in two consecutive years (the latter
provision was changed to require divestment only once a company achieves a cumulative profit).
Prior to the financial crisis, a large number of Indonesian banks maintained correspondent
relationships with American banks. However, given the fundamental restructuring underway in the
banking system, many of these relationships are no longer in effect.
- 54 -

With the sharp drop-off of private capital flows since the economic crisis, Indonesia is now heavily
dependent on official financing, primarily from the Asian Development Bank (ADB), World Bank,
and major bilateral donors. The World Bank, ADB, and other multilateral and bilateral donors meet
periodically in the Consultative Group on Indonesia (CGI).
4.
How to finance exports/methods of payment
Since the onset of the crisis, the Government of Indonesia has taken a number of steps to encourage
private sector lending. Indonesia retained an open capital account with no foreign exchange controls
both during and after the crisis. The May 1999 foreign exchange law requiring banks and other
businesses to report large foreign exchange transactions for monitoring purposes has not had a
significant effect on capital flows.
The GOI has also implemented specific measures aimed at increasing the supply of trade financing,
including: Establishment of a US$ 1 billion collateral fund deposited offshore to encourage
acceptance of Indonesian letters of credit (set up in mid-1998); Government insurance for repayment
of trade financing extended by Indonesian banks (set up in late 1998, but little used); Establishment in
July 1999 of Bank Ekspor Indonesia, a Trade Maintenance Facility arising from the June 1998
"Frankfurt Agreement" (renewed in May 2000). Creation of a $1 million short-term credit guarantee
program in collaboration with foreign export credit agencies, including the US Export-Import Bank.
5.
Types of available export financing and insurance
Prior to the financial crisis, all forms of import and export financing were available in the Indonesian
market and frequently used, although most imports were financed with letters of credit. Short-term
financing was readily available. Some larger banks were providing longer-term financing of up to 2-3
years.
Indonesian buyers have generally preferred the supplier to provide the necessary financing for a
commercial transaction, either normal commercial trade financing or export credits from the source
country's export credit agency (for e.g in the case of the United States, the US Ex-Im Bank located in
Washington, D.C.).
Local bank financing has sometimes been arranged, depending on the customer or the
agent/distributor involved in the transaction. Once the economy recovers, proposed reforms in the
banking sector should make local financing a more favorable option than it has been in the past.
Several American banks have shown initiative in arranging trade-financing packages for their
customers, some with Ex-Im Bank guarantees. Although U.S. Ex-Im, along with other export credit
agencies and foreign banks, is not processing applications in Indonesia currently, once bankers have a
reasonable assurance that stability is returning to Indonesia, investors will rely on creative financing
options more than ever.
Indonesia now secures a substantial portion of its development funding from the multilateral
development banks, primarily the Asian Development Bank (ADB) and the World Bank. Indonesia
will rely on this assistance to a larger extent.
- 55 -
N. Trade promotion
1.
Ministry of Trade and Industry (http://www.dprin.go.id)
The Ministry of Trade and Industry's mission is to promote Indonesian small and medium enterprises
to the global market place. It is also the coordinating and regulatory agency for counter trade deals.
2.
National Agency for Export Development (http://www.nafed.go.id)
The Indonesian Government established the National Agency for Export Development within the
Ministry of Trade to promote the export of less renowned products. These products include
handicrafts (i.e., jewelry, batik, hand-woven fabric, and wood carvings), agricultural and cottage
industry products, and new manufactured products. The agency will also assist foreign buyers and
importers in establishing contacts with Indonesian companies.
The role of the NAED involves coordinating, encouraging and implementing the development of
national export through market information services and implementation of export promotion.
The mission of Nafed are as follows:
To formulate policy and establish guidelines for encouraging and supporting the expansion of nonoil and gas exports
To provide information services and market co-ordination
To implement and co-ordinate export promotion
To expand the range of export products and markets
The Agency maintains a database of thousands of Indonesian manufacturers classified by product as

well as another database of foreign buyers who may be of interest to Indonesian exporters. All
NAFED services are free of charge and, as a non-profit organization, NAFED acts as a facilitator
linking buyers and sellers. The Agency places special emphasis on expanding the export of non-oil
and gas commodities, for years once the mainstay of the economy.
It is proactive in identifying manufacturers with suitable products for sale overseas as well as
identifying new markets overseas. A substantial portion of Indonesia s export growth is a result of the
activities of NAFED together with private companies in penetrating new and non-traditional markets.
NAFED s goal is to assist the Indonesian business community and the country s exporters in
particular, to produce and export products which attract market interest and fulfill market demands.
An important means of achieving this is the product adaptation and development programme, which is
undertaken through technical support from domestic and international experts and co-operation
between Government, private sector and university institutions.
- 56 -
3.
Indonesian Chamber of Commerce and Industry (http://www.kadin-indonesia.org.id)
The major trade association in Indonesia is the Indonesian Chamber of Commerce and Industry
(KADIN). Members include representatives from private industry, cooperatives, public corporations,
utilities, as well as state-owned enterprises. In addition, there are numerous other specialized and
professional organizations that represent the interests of various other sectors and trades in the
economy.
Business and government leaders of Indonesia officially established the Indonesian Chamber of
Commerce and Industry in 1968 as a result of the joint efforts. The KADIN is an independent, nongovernmental, non-profit making economic/business organisation - the sole organisation uniting
Indonesian entrepreneurs and the business world, representing all private enterprises and State
enterprises.
As an economic organisation uniting national entrepreneurs, the KADIN consists of (Central) KADIN
Indonesia, KADINDA, business/trade Associations, the 'Himpunan' or other national economic
organisations and the Committees of Foreign Economic Cooperation. It also serves as a forum and a
facilitator for promoting and enhancing the vital roles of businessmen in Indonesia, increasing
business interaction and enhancing regional economic growth.
Kadin Indonesia directs its activities to bridging the gaps which exist among the entrepreneurs and
functions as a mediator between business communities and the government. With economic cooperation as one of its main focus, Kadin Indonesia regularly holds various kinds of meetings,
workshops, issues publications and establishes an information network to facilitate contact and
exchange of information among businessmen. Indonesia has brought thousands of business leaders
and key entrepreneurs from all parts of the world into personal contacts, business meetings and one on
one meetings.
Kadin Indonesia provides direct services to 26 provincial chapters and more than 300 regencies'
branches. It is constantly reviewing its activities to be relevant to the situations. It is constantly
reviewing its activities to be relevant to the situations. Over 200 business associations are part of the
Chamber structure.
To coordinate its activities with other countries or regions, Kadin Indonesia established committees,
bilateral or multilateral, and forms linkage and collaborates with key regional and international groups
and chambers, both private and governmental, whose objectives and purposes are similar to its own.
4.
GP Farmasi (Gabungan Perusahaan Farmasi Indonesia) / Indonesian Association of

Pharmaceutical Companies (http://www.gpfarmasi.co.id)
GP Farmasi is the reference point for the pharmaceutical industry in Indonesia. In its present form it
came into existence on the 19th August 1969. The association has the following constituents:
G.A.S.I (Gabungan Apotik Seluruh Indonesia) Pharmacy/Dispensary Association
P.I.PH.I. (Persatuan Importir Pharmasi Indonesia) Pharmaceutical Importers Association
G.A.F.I (Gabungan Industri Farmasi Indonesia) Pharmaceutical Industry Association (others

including manufacturers)
- 57 -

The objectives of the association are to promote sharing of the pharmaceutical domain knowledge
within the economy, and to contribute to the development of the national economy by providing
inputs to the government (on matters concerning healthcare and the pharmaceuticals industry).
As of September 2002, GP Farmasis members only include firms with legal operating licenses,
comprising 198 manufacturers, 2,500 distributors, 6,500 dispensaries and 5,000 drug stores.
O. Conclusions and recommendations

1.
Overview
The pharmaceutical industry in Indonesia has been well established compared with other industries in
the country. It has particularly developed since 1955 when there were only seven pharmaceutical
plants in the country. It then began to grow significantly in the 1960s, especially after the introduction
of the Foreign Capital Investment Law in 1967 and the Domestic Capital Investment Law in 1968.
Already in 1966 this number had risen to 130. The number of plants continued to increase after the
introduction of the Investments Law. By 1975 there were 230 factories, in 1984 there were 273 and in
1988 the figure rose to 285, and currently there are 208 such plants.
The development of the pharmaceutical industry was paralleled by other related businesses, such as
wholesalers.
Given the distribution of population, skills and infrastructure, it is not surprising that most of
Indonesia's pharmaceutical plants are located in Java. In 1955, 243 or 88.7% of pharmaceutical plants
operating in Indonesia were located in Java (currently 93.4%), with the largest number in Jakarta and
West Java. These two regions had a total of 142 factories in 2007 (currently 130), East Java had 56
(currently 54), Central Java had 30 (number unchanged to the current period) and Yogyakarta had 5.
Outside Java, North Sumatra topped other regions with 17 factories (currently 10).
Of interest to a foreign company aspiring to enter the Indonesian market would be the tally of the 35
foreign joint venture companies, although small in number, have established a strong market share in
Indonesia. Most of them are multinational companies. (see table below)
- 58 -
Pharmaceutical manufacturer
Location
PT. Abbott Indonesia

PT. Bayer Indonesia
PT. Beecham Pharmaceutical
PT. Beidersdorf Indonesia
PT. Bristol Myers Indonesia
PT. Burroughs Wellcome Indonesia
PT. Carlo Erba Farmatalia
PT. Ciba Geigy Pharma Indonesia
PT. Dmex Indonesia
PT. Eisia Indonesia
PT. Essex Indonesia
PT. Galxo
PT. Hoechst Pharmaceutical
PT. Hudson Indonnesia
PT. ICI Farmasi Indonesia
PT. Johnson & Johson Indonesia
PT. Medifarma Laboratories
PT. Meiji Indonesia
PT. Merck Indonesia
PT. Merrel Dow Pharm
PT. Nattermann Indonesia
PT. Nicholas Laboratories Ind.
PT. Nordmark
PT. Organon Indonesia
PT. Otsuka Indonesia
PT. Parke-Davis
PT. Pfizer Indonesia
PT. Pfrimer Indonesia
PT. Pharma Indonesia
PT. Rhone Poulenc Indonesia
PT. Richardson Vicks Indonesia
PT. Roche Indonesia
PT. Salonpas Indonesia
PT. Sandoz Biochemie Farma
PT. Schering Indonesia
PT. Squibb Indonesia
PT. Sterling Product Indonesia
PT. Takeda Indonesia
PT. Upjohn Indonesia
PT. Warner Lambert Indonesia
Source: P.T. Corinthian (CIC)
West Java
Jakarta
Jakarta
East Java
West Java
West Java
West Java
Jakarta
Jakarta
West Java
East Java
Jakarta
Jakarta
West Java
East Java
East Java
Jakarta
East Java
Jakarta
Jakarta
West Java
Jakarta
Jakarta
Jakarta
Jakarta
Jakarta
Jakarta
West Java
West Java
West Java
Jakarta
West Java
Jakarta
East Java
Jakarta
West Java
West Java
West Java
West Java
West Java
- 59 -
2.
Recommendation on Market Access
The pharmaceutical and raw material market in Indonesia is very sensitive and dynamic. The market
for medicines depends largely on the pattern of the common diseases in a country. In tropical and
developing countries, infectious diseases are the most common. For example, acute exhalation
channel infection amounted to 15.1% in 2005. Tooth and gum disease are second in prevalence,
attacking 8.0% of the population. Skin and hypodermic diseases are third, accounting for 7.5% of
cases. Eye and adnexa diseases amount to 6.2% and cardiovascular diseases for 2.6%. This
composition has not changed much during the last several years, with one exception: upper and lower
respiratory tract cases have increased from 38.3% in 1987 to 41.0% in 2003 (possibly due to the
considerable air pollution in all population centers).
Apotik sales of medicines reflect the characteristics of the pharmaceutical market in Indonesia.
Antibiotic sales from apotiks accounted for 42.9% of the country's total sales of pharmaceuticals,
topping other pharmaceuticals in sales. Respiratory system drugs are the second largest selling group
of pharmaceuticals, sharing 12.6% of the country's total sales of pharmaceuticals. These two
pharmaceuticals make up 50% of the country's total drug sales. This % age corresponds to the pattern
of common diseases in the country.
Drugs for the neuromuscular system held 11.6% of the pharmaceutical market, placing third in sales
followed by vitamins and minerals, which shared 10.3% of the market. Details are shown in the table
below.
- 60 -
3.
Market share of pharmaceutical products (by sales)

Pharmacological Classification/
SubClassification
Antibiotic
Penicillin (51.4%)
Macrolide (12.6%)
Chloramphenicol (9.6 %)
Ohers (26.4 %)
Total
Respiratory system
Cough & Cold Remedies (82.6%)
Antiasthmatic Preparations (15.7%)
Others (1.72%)
Total
Neuromuscular
Analgesic & Antipyretic (32.2%)
Antihistamine & Antiallergic (16.6 %)
Antiinflammatory Enzyme (8.8%)
Others (32.0%)
Total
Vitamin & Minerals
Vitamin B Complex (24.1%)
Multivitamin & Mineral (22.3%)
Appetite Stimulant (12.3%)
Antianaemics (10.7%)
Others (30.6%)
Total
Dermatological Drugs
Antiinfective w/Corticosteroid (33.9%)
Fungicides & Antiparasites (15.8%)
Topical Corticosteroid (15.4%)
Anti-infective (10.7%)
Others (24.3%)
Total
Other Chemotherapeutics
Other Antituberculous Agent (41.6%)
Anti Diarrheals (18.0%)
Others
Total
Cardiovascular system & diuretic
Alimentary system
Nutritive Drugs
Hormone Drugs
Others
Source: P.T. Corinthian (CIC)
- 61 -
Market
Share (%)
26.3
12.6
11.6
10.3
9.4
6.1
5.9
5.7
3.2
2.2
6.6

4.
Recommendations
(a)
Exporting
For a company at the beginning of the learning curve (re the Indonesian pharmaceutical market),
exporting through pharmaceutical wholesalers in Indonesia is good strategy before committing greater
resources to the market.
(b)
Establishing pharmaceutical plants in Indonesia (supplied with imported basic ingredients)
The large market demand for pharmaceutical products has not encouraged investment in basic
ingredient manufacturing. About 95% of the basic ingredients are supplied through imports; only 5%
come from local sources. Despite government encouragement, no domestic investor has been
interested in venturing into the pharmaceutical basic ingredients industry. Technological and
marketing problems, coupled with the difficulties of obtaining manufacturing licenses from foreign
principals, are among the obstacles discouraging investors from committing to this business.
Foreign joint venture companies receive basic ingredient supplies from their parent companies abroad
and, without government requirements, would most likely eliminate their costly chemical plants in
Indonesia. Imports are expected to fill the basic ingredient supply in the future.
This is the strategy taken by many multinational companies in Indonesia (Merck, Bayer, Glaxo,
Schering, Squibb, etc.) i.e. to set up a pharmaceutical plant in Indonesia, which is supplied by basic
ingredients and raw materials that they produce overseas. Such captive local plants are least affected
by changing supply conditions barring the economic crisis (which skyrocketed the costs of imports),
and are stronger than the local pharmaceutical companies.
(c)
Establish a plant to produce active ingredients
Finally a company can enter the Indonesian market by establishing a plant to produce active (basic)
ingredients. Notwithstanding the tremendous government support such a venture is anticipated to
receive, the problem of economies of scale would be paramount.
The relatively small active pharmaceutical ingredient market in Indonesia raises the question of
profitability of such a plant, and an entrant under this mode would need a complimentary strategy of
exporting (active ingredients) from its Indonesian base.
For a multinational company, the following exhibit best encapsulates the target and strategy for the
Indonesian market.
(d) The government should not intervene on the prices of generic medicines that hold the logo (OGB).
In other word, prices of generic drugs with the logo should be left to the market mechanism and to
consumers demand, to encourage private pharmaceutical companies to enter the market.
- 62 -
- 63 -
IV.
USEFUL ADDRESSES
GOVERNMENT BODIES AND INDUSTRY ASSOCIATIONS

Ministry of Industry And Trade - The Republic of Indonesia
Jl. Gatot Subroto Kav. 52-53, Jakarta 12950, Indonesia
Phone: (62-21) 5252194
Facsimile: (62-21) 5261086
E-mail Address: pusdata@dprin.go.id
Website: www.dprin.go.id
Ministry of Health
Jl. H.R. Rasuna Said Blok X/5 Kav 4-9, Jakarta, Indonesia
Phone: (62-21) 5201590
Website: www.depkes.go.id
Directorate General of Drugs and Food Control
Jl. Percetakan Negara No. 29, Jakarta, Indonesia
Phone: (62-21) 4245459, 4244755, 4244691, 4244688
Directorate General of International Trade
Jl. Gatot Subroto Kav. 52-53, Jakarta, Indonesia
Phone: (62-21) 3860940, 3858195, 3858201, 3858194
GP Farmasi / Indonesian Association of Pharmaceutical Companies
Jl. Angkasa No. 20 A Kemayoran, Jakarta Pusat 10260, Indonesia
Phone: (62-21) 4203040
Facsimile: (62-21) 4203047/48
Email: sekertariat@gpfarmasi.org, munas@gpfarmasi.org
Website:http://www.gpfarmasi.org
Indonesian Chamber of Commerce and Industry (KADIN)
Gedung Menara Kadin 29th Floor, Jl. Rasuna Said, Jakarta 10350, Indonesia
Phone: (62-21) 324000
Email Address: Inquiry@kadinnet.com
Website: http://www.kadin-indonesia.org.com
National Agency For Export Development (NAFED)
Ministry of Industry and Trade, Jalan Gajah Mada No. 8, Jakarta 10310, Indonesia
Phone: (62-21) 634 1082
Facsimile: (62-21) 633 8360
Email Address: nafed@nafed.go.id
Website: www.nafed.go.id
- 64 -
Central Bureau of Statistics

Jl. Dr. Sutomo 6-8, Jakarta 10710, Indonesia
Phone: (62-21) 350 7057
Facsimile: (62-21) 385 7046
Website: http://www.bps.go.id
Investment Coordination Board (BKPM)
Jalan Jenderal Gatot Subroto No.44, Jakarta 1210, Indonesia
Phone: (62-21) 525 2008
Facsimile: (62-21) 525 4945
Email: sysadm@bkpm.go.id
Website: www.bkpm.go.id
MINISTRY OF HEALTH (DEPARTEMEN KESEHATAN)

Minister of Health : DR. Dr. Siti Sadilah Supari, Sp.B, MHA
Jl. HR Rasuna Said Blok X-5 Kav. 4-9, 2nd floor Block A
Jakarta Pusat
Phone: (021) 5201587, 5201591
Sentral: (021) 5201590
Fax: (021) 5201591
Advisor on Pharmaceutical Medical : DR. Bambang Giatno Raharjo MPH
Jl. HR Rasuna Said Blok X-5 Kav. 4-9, 2nd floor Block B Room 218
Jakarta Pusat
Phone: (021) 5203882
Fax: (021) 5201590
General Inspector : DR. Faiq Bahfen
Jl. HR Rasuna Said Blok X-5 Kav. 4-9, 2nd floor Block A Room 209
Jakarta Pusat
Phone: (021) 5201601
Sentral:5201590 ext 2100-2101
Director General for Community Health : Dr. Edi Suranto MPH
Jl. HR Rasuna Said Blok X-5 Kav. 4-9, 2nd floor Block B
Jakarta Pusat
Phone: (021) 5221228-5277217
Director General of Medical Services: Dr. Yulizar Darwis Sp. KJ. MM
Jl. HR Rasuna Said Blok X-5 Kav. 4-9, 2nd floor Block B
Jakarta Pusat
Phone: (021) 5222429
Sentral: (021) 520021-5222429
Email: yadmed@depkes.go.id
- 65 -
Director General of Communicable Disease Control: Dr. Erna Treshnaningsih MOH Ph.D.
Jl. Percetakan Negara No. 29, Jakarta, Indonesia
Phone: (021) 4209930
Sentral/021) 4247608 ext 100
Director General of Pharmacies and Health Equipment Services: Drs. Bahdar J Hamid, M Pharmasi
Jl. HR Rasuna Said Blok X-5 Kav. 4-9, 2nd Block B Room 220
Jakarta Pusat
Phone: (021) 5214874-9227224
Sentral: (021) 5201590 ext 6309-6302
Director of Rational Medicine Application: Dra. Nani Sukasedati MS
Jl. HR Rasuna Said Blok X-5 Kav. 4-9, 6th floor Block B
Jakarta Pusat
Phone: (021) 5201590(hunting) ext. 6309
Fax 021 521487
Sentral: 021 5201590 ext6309-6302
Director for Production and Distribution of Health Equipment: Drs. Bahdar J Hamid, M Pharmasi
Jl. HR Rasuna Said Blok X-5 Kav. 4-9, 2nd Block B Room 220
Jakarta Pusat
Phone: (021) 5214874-9227224
Sentral: (021) 5201590 ext 6309-6302
NATIONAL AGENCY FOR DRUGS AND FOOD CONTROLS BADAN PENGAWASAN

OBAT DAN MAKANAN (BPOM)
Chairman : Drs. H. Sampuno, MBA
Jl. Percetakan Negara no. 23
Jakarta Pusat 10560
Phone: (021) 424 4688
Facsimile: (021) 425 0764
Email : spn@indo.net.id
Website : www.pom.go.id
Primary Secretary (Sekretaris Utama) : Mrs. Mawarwati Djamaluddin
Jakarta Pusat 10560
Phone: (021) 424 5331
Facsimile: (021) 424 4947
Email: sestamapom@yahoo.com
Deputy I Theurapetic & Narcotic Inspection : Dra. Lucky S. Slamet, M.Sc.
Jakarta Pusat 10560
Phone: (021) 424 5459, 424 4755 ext. 103
Facsimile: (021) 424 3605
Email: deputi1@pom.go.id
- 66 -
Deputy II Therapeutic & Narcotic Inspection : Drs. Ruslan Aspan, MM.

Jakarta Pusat 10560
Phone: (021) 4288 4208
Facsimile: (021) 4288 4208
Email: deputi2@pom.go.id
Director of Therapeutic Product Standardization : Mr. Udjianto
Jakarta Pusat 10560
Phone: (021) 424 5459, 424 4755 ext. 105
Facsimile: (021) 424 3605
Email: standarterapetik@pom.co.id
Head of Sub. Dit. Chemical Industry : Mrs. Frida
Jakarta Pusat 10560
Phone: (021) 424 5459, 424 4755 ext. 105
Facsimile: (021) 424 3605
Email: standarterapetik@pom.co.id
Head of Drugs Registration : Mrs. Retno Tiasutami
Jakarta Pusat 10560
Phone: (021) 424 5459, 424 4755 ext. 110
Facsimile: (021) 4288 5404
Email: retnoty@yahoo.com
Head Sub. Dit. Drugs Registration : Mrs. Endang Woro
Jakarta Pusat 10560
Phone: (021) 424 5459, 424 4755 ext. 105
Facsimile: (021) 4288 5404
Email: penilaianobat@pom.go.id
- 67 -
V.
REFERENCES
PUBLICATIONS
ASEAN Meeting Report
1. Developments from ASEANs ACCSQ Pharmaceuticals Product Working Group, Manuel Zahn
reports on the fourth meeting of the ACCSQ PPWG held 2529 September 2001 in Bali,
Indonesia
2. Overview Of Asia, Healthcare Markets And Regulatory Issues In The Region: Presentation At
Raps, August 2001, Ames Gross, President, Pacific Bridge, Inc., August 2001
3. Update On The Asian Economies And Major Healthcare Trends, Ames Gross, Pacific Bridge, Inc.
September 1998
4. Survey on Pharmaceutical industry in Indonesia, 2002, Bukhari
5. The market for pharmaceutical products and materials in Indonesia, 2004, PT Data Consult
6. P.T. Pharma Indonesia, Gunter Dufey, Priscilla Rogers, Andreas Bunanta, Michigan Business
School
7. Promoting Rational Use Of Drugs at The Community Health Centers In Indonesia, Arustiyono,
Department Of International Health, School Of Public Health, Boston University, September 1999
8. The Exporters Encyclopedia 2000/2001. New York, 2000. Dun and Bradstreet International.
9. Rochaini, Aulia. 2000. Development of Paper and packaging industry. Retrieved on 06 Nov
2002 from http://www.tradeport.org
10. Worldwide corrugated packaging industry statistics report. International corrugated case
association, 2002
11. Pacific Business and Industries. Vol.III 1996, (33): 44-49
12. Indonesia: General features of trade policy. 2002. Market Access sectoral and trade barriers
database. Retrieved on 06 Nov 2002 from: http://www.mkaccdb.eu.int/mkdb/chksel.pl
13. Indonesia: Strategy for manufacturing competitiveness, Dhanani, Shafiq, UNIDO, Jakarta, 2000
14. MIMS Indonesia
15. A supply and demand survey on active ingredients/raw materials for Indonesia, Sulaeman
Krishnandhi, January 2000
16. Indonesian Commercial Newsletter; November 5, 2002
17. P.T. Corinthian (CIC)
18. Pharmaceutical Report, PT ARCI, 2005
19. Indonesian Statistics, 2007 and www.bps.go.id
20. Indonesian Healthy Profile, 2007 and www.depkes.go.id
21. Macroeconimics and Health Inititaive in Indonesia WHO, 2006.
- 68 -
World Wide Web Resources

1.
US ASEAN Business council (www.us-asean.org)
2.
GP Farmasi / Indonesian Association of Pharmaceutical Companies (www.gpfarmasi.org)
3.
Pharma info (www.pharma-info.com)
4.
Global Sources (www.globalsources.com)
5.
Economist Intelligence Unit (www.eiu.com)
6.
Pacific Bridge, Inc (www.pacificbridgemedical.com)
7.
University of Michigan (www.umich.edu)
8.
Bank Indonesia (www.bi.go.id)
9.
Asia Pacific Economic Cooperation (www.apecsec.org.sg)
10.
Asian Development Bank (www.adb.org)
11.
Australian Trade Commission (www.austrade.org.au)
12.
U.S Department of Commerce National Trade Data Bank (www.tradeport.org)
13.
The Jakarta Post (www.thejakartapost.com)
14.
Asia Times Online (www.atimes.com)
- 69 -
COMPANY/PRODUCT PROFILE FORMS
- 70 -
COMPANY PROFILE FORM

ASIAHEALTHCARE 2008
Malaysia, March 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Dr. Ping Ping Hartono / Marketing Director

PT Astra Zeneca
Gd Arkadia Tower c Lt. 11, Jl. TB. Simatupang kav 88
Jakarta - Indonesia
Tel: 78835777
Fax: 021 78836222
Bank Ref: HSBC
Legal status:
Other office(s) location(s):
Headquarters location:
Website:
Quality certification (ISO; GMP):
Annual turnover (USD):
Share exported (%):
Current export/import markets:

Registration with export promotion bodies, chambers of commerce, business associations (specify):
ACTIVITIES
Manufacturer/Producer
Wholesaler/Retailer
Trader
Service provider: quality control, packaging, machinery, business

information (specify):
EXPORT/IMPORT INTEREST
Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
General anaest. & oxygen
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics
Preoperative med. and sedation
Analgesics, Antipyretics, Anti-inflammatory, Non-steroidal (NSAIMs), medicines used to treat

gout and disease modifying agents in rheumatoid disorders (DMARDs):
NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Antiallergics and medicines used in anaphylaxis
Antidotes and other substances used in poisoning:
Non-specific
Specific
Anticonvulsants / Antiepileptics
Anti-Infective medicines:
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
Antimigraine medicines:
For treatment of acute attack
For prophylaxis
Antineoplastic, Immunosuppressives and medicines used in palliative care:
Immunosuppressive
Cytotoxic medicines
Hormones and antihormones
Medicines used in palliative care
Antiparkinsonism medicines
Medicines affecting the blood:
Antianaemia medicine
Medicines affecting coagulation
Blood products and plasma substitutes:
Plasma substitutes
Plasma fractions for specific use
Cardiovascular medicines:
Antianginal
Antiarrhythmic
Antihypertensive
Used in heart failure
Antithrombotic
Lipid-lowering
Dermatological medicines:
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Skin differentiation /proliferation
Scabicides/pediculicides
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Disinfectants and Antiseptics:
Antiseptics
Disinfectants
Diuretics
17
Gastrointestinal medicines:
18
Antacids and other antiulcer

Antiemetic
Laxatives
Used in diarrhoea
Hormones, other endocrine medicines and contraceptives:
Adrenal/synthetic substitutes
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Insulins/oth. Antidiab.agents
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
Sera and immunoglobulins
Muscle relaxants (Peripherally-acting) and cholinesterase inhibitors
21
Ophthalmological preparations:
22
Anti-infective agents
Miotics and antiglaucoma
Oxytocics and Antioxyytocics:
23
Oxytocics
Peritoneal Dialysis Solution
24
Psychotherapeutic medicines:
Anti-inflammatory agents
Mydriatics
Local anaesthetics
Used in mood disorders

Used in obsess. compulsive disorders &
panic attacks
Used in generaliz. anxiety & sleep disorders
27
Vaccines
Antioxytocics (tocolytics)
Used in psychotic disorders
26
Thyroid hormones/antithyroid medicines
19
25
Used in substance dependence programmes

Medicines acting on the respiratory tract
Antiasthmatic and medicines for chronic
Other medicines acting on the respiratory
obstructive pulmonary disease
tract
Solutions correcting water, electrolyte and acid-base disturbances:
Oral
Parenteral
Miscellaneous
Vitamins and Minerals
NATURAL RAW MATERIALS, EXTRACTS & OILS

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
Ajowan (seed) fruit (Trachyspermum ammi)

Aloe Vera ( A.vulgaris lam)
Amla fruit (Phyllanthus emblica)
Arjuna (Terminalia arjuna)
Artemisia (Artemisia annua)
Asafoetida oleoresin (Ferula asafoetida) or Oleogum resin
Ashwaagandha (Withania somnifera)
Astragalus root pwd (Astragalus membranaceus)
Belleric myrobalan fruit (Terminalia bellerica
Bosewellia (Bosewellia serrata)
Caralluma extract(Caralluma fimbriata)
Chebulic myrobalan fruit (Terminalia chebula)
Cherokee rose hip (Rosa laevigata)
Chicory root (Cichorium intybus)
Chinese Hibiscus (Hibiscus rosasinensis)
Chirata herb (Swertia chirayita)
Corydalis (Corydalis yanhusuo)
Dang gui (Angelica sinensis)
Eleuthero root (Eleutherococcus senticosus)
Epimedium herb (Epimedium brevicornum)
Garcinia Fruit (Garcinia bambogea)
Garlic bulb (Allium sativum)
Ginger rhizome (Zingiber officinale
Ginkgo leaf (Ginkgo biloba)
Ginseng root (Panax ginseng)
Green tea (Camellia sinensis)
Gotu Kola (Centella asiatica)
Guduchi (Tinospora cordifolia)
Guggul (Commiphora mukul)
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85
Gymnema (Gymnema sylvestre)

Gynostemma herb (Gynostemma pentaphyllum)
Hawthorn (Fructus crataegi)
Hop strobile (Humulus lupulus)
Jujube date powder (Ziziphus jujuba)
Kelp thallus (Laminaria japonica)
Kudzu root ( pueraia lobata)
Licorice root (Glycyrrhiza uralensis)
Lycium fruit (Lycium barbarum)
Madagascar Periwinkle (catharanthus roseus)
Magnolia bark (Magnoliae officinalis)
Manjishta (Rubia cordifolia)
Neem leaf (Azadirachta indica)
Niuri (Phyllanthus amarus)
Parmelia lichen extract (Parmelia cryptochloropbaea)
Prisniparni (Uraria picta)
Psyllium husk (plantago ovata)
Rhodiola (Rhodiola rosea)
Safed musli tuber (Chlorophytum borivillianum
Sandalwood heartwood (Santalum album)
Sargassum alga (Sargassum pallidum)
Sarpagandha (Rauwolfia serpentia)
Schisandra fruit (Schisandra chinensis)
Sea buckthorn (Hippophae rhamnodies)
Shatavari root (Asparagus racemosus)
Star anise fruit (Illicium verum)
Tribulus terrestris (Tribulus zygophyllacae)
Vanilla fruit (Vanilla planifolia)
Velvet bean (Mucuna pruriens)
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88
Binders (pre gelatinized cellulose, lactose)

Compression aids (dextrose, lactose, microcrystalline
cellulose)
87
Colors (titaium dioxide)
89
Disintegrants (sodium starch glycolate, croscarmellose)
I
I
E
E
90
Fillers/diluents (dicalcium phosphate, starches sucrose)
91
92
Flavours (Sodium chloride, citric acide)
93
94
Lubricants (Magnesium stearate, talc)
95
96
98
Suspensing / dispersing agents (gelatins, starches, gums)
97
Others (specify):
Film formers/coating (maltodextrin, hydroxyl, methyl

prophyl cellulose
Glidants (flow enhancers) (silicon dioxide, cellulose,
titanium dioxide, talc)
Preservatives (citric acid, sodium citrate, methyl
paraben)
Sweeteners (surcrose, fructose, dextrose annitol)
INTEREST IN OTHER BUSINESS PARTNERSHIPS

My company is seeking for:
My company is offering:
Joint sourcing
Joint distribution
Complementary production
Concerted marketing / promotion
Technology transfer
Development of new product / technology
Product registration
Contract manufacturing
Other (specify):
OTHER INFORMATION
To obtain maximum benefit from your participation in AsiaHealthCare 2008, it is highly important that you bring full
details regarding your product specifications and quality standards, indicative prices, stock availability, production
capacity, information about your company, and customer references. You may also wish to bring a large supply of
business cards and brochures, which will contribute to the success of your business consultations. Space for the
display of a limited range of samples will be available. A detailed programme and request to confirm your
participation will be sent to you within the next weeks. For more information, please contact ITC at:
betemps@intracen.org

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Inge Kartono/Marketing Manager

PT Bayer Schering Pharam Indonesia
Mid Plaza It. 14-16 Jl. Jenderal Sudirman Kav 10-11
Jakarta - Indonesia
Tel: 6221-5703661
Fax:
Bank Ref:
Legal status:
Headquarters location: Jakarta
Website: www.bayer.co.idl

Share exported (%):
ISO 9001:2000
Australia, Germany, Brasil, Thailand, Singapore, Korea
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
marketing@bernofarm.com
Year established: 1971
Hartoko (Director) / Hariyanto (Ass. Director)

PT Bernofarm
Komplek Harmoni Plaza J3-J4 Jl. Suryopranoto
Jakarta Pusat 10130 - Indonesia
Website: www.bernofarm.com
Tel: 6318949
Fax: 6318948
Bank Ref: BCAi
Legal status: Local Company


Share exported (%):
9001-2000
Swiss, India (import)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: pre@bintang7.com
PRE Agusta Siswantoro (Manufacturing Director)

PT Bintang Toedjoe
J. Rawa sumur Barat II K.9 Pulogadung
Jakarta, Indonesia
Tel: 6221-4605 533
Fax: 6221-4605 535 / 4613 632
Bank Ref: NA
Legal status: NA
Other office(s) location(s): Pulagadung
Headquarters location: Pulomas
Website: www.bintang7.com

Annual turnover (USD): NA
Share exported (%): NA
ISO, GMP, OHSAS
Asean (Philippines, Malaysia, Vietnam)
NA
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify): SOD Bicarnonane

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Drs. Andreas Eka Sinarjo. Apt/Director

PT Biolife Medilab
Jl. Cawang Baru Tengah No. 8
Jakarta, Indonesia
Tel: 21-8195 260
Bank Ref: BCA
Website:
Fax: 21-8577 477

Share exported (%):

China, Europe
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Andrew Eve - Presidetn Director
Company name:
PT Boehringer Ingelheim Indonesia
Street POB:
Wisma Standard Chartered Bank, Lt 11, Jl. Jenderal Sudirman Kav 33-A
City Country:
Jakarta - Indonesia
Email:
Tel: 62-21-5732 375
Fax: 62-21-573 2383
Year established:
Bank Ref: BCA
Legal status: Foreign Company
Website: www.boehringerOther office(s) location(s):
ingelheim.com
Share exported (%):
ISO 9001
All Asia
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Jack Pradono handoyo

PT Bristol Myers Squibb
Tamara Centre Lt. 10 Jl. Jenderal Sudirman Kav. 24
Jakarta, Indonesia
Tel:
Fax:
Bank Ref:
Legal status:
Website:
Share exported (%):

Thailand, Japan, Malaysia, USA
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
B. Wanandi - President Director

PT COMBIPHAR
Jl. Tanah Abang II No. 19
Jakarta JKP 10160 - Indonesia
Tel: 62-21-38808 008
Bank Ref: BCA
Website:
Fax: 62-21-3808 009

Legal status:
Share exported (%):

Japan, China (Import)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
timotius@dankosfarma.com
Mr. Timotius Yan Hokianto

PT DANKOS FARMA
Jl. Rawa Gatel Blok III S, Kav. 37-38, Kawasan Industri Pulogadung
Jakarta 13930, Indonesia
Website:
Tel: 6221-4600 158
Fax: 6221-4611 301 / 4601 053
Bank Ref: Citibank, Permata Bank
Legal status: PT Limited Company


Share exported (%):
ISO 9001, GMP
Nigeria, Myanmar, Cambodia
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify): MOST OF RAW MATERIAL

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: ricardo.sopacua@daryavaria.com
Website: www.darya-varia.com.
Ricardo A. Sopacua - Business Development Manager

PT Darya-Varia laboratoria Tbk
Jl. Melawai raya No. 93
Jakarta Selatan - Indonesia
Tel: 62-21-725 8010
Fax: 62-21-725 8011
Bank Ref: HSBC Jakarta
Legal status: Public Company


Annual turnover (USD): 65 mio
Share exported (%):

ASEAN, West Africa, Middle East
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Ferry A. Soetikno / Director Manager

Dexa Medica Group
Graha Elnusa Building Lt. 5, Jl. TB. Simatupang Kav. 1B
Jakarta, Indonesia
Tel: 62-21-7883 0884
Fax: 62-21-7884 6464
Bank Ref:
Legal status: Local company
Website:

Share exported (%):
9001
Myanmar, Vietnam, Cambodia, Philippines, Singapore, Malaysia, Nigeria
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Tjipto Pusposuharto / J. Haryanto Santoso

PT Dipa Pharmalab Intersains
Jl. Kebon Jeruk Raya 66
JKB 11530 - Indonesia
Tel: 5350535
Bank Ref:
Website: www.dipa.co.id
Headquarters location: J
Fax: 5481322 / 53675269

Legal status:

Share exported (%):
9001
Germany, Switzerland, USA, Japan, China (I)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Devi Ariyani (Head of Business Marketing)

PT Dksh
Jl. Gatot Subroto Menara Jamsostek Lt22
Jakarta - Indonesia
Tel: 5228338
Bank Ref: Duetche banki
Website: www.dksh.com
Fax: 5228337
Legal status: PMA

Share exported (%):
ISO 9001
Germany, Thailand, Singapoer, Switzerland, USA (Import)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Rusdi Irwan - Director

PT ETHICA
Kawasan Industri Pulogadung No. 46
Jakarta Timur - Indonesia
Tel: 62-21-4615133
Bank Ref: BCA
Website: www.ethica.com
Fax: 62-21-4615135
Legal status: PMDN
Share exported (%):

All Asia
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Rudy Soetiknoi
Company name:
PT Ferron Phamaceuticals
Street POB:
Graha Elnusa, 3rd Floor Jl. TB Simatupang Kav 1B
City Country:
Jakarta Sel 12560 - Indonesia
Email: info@ferron-pharma.com
Tel: 78843633
Fax: 78843638
Bank Ref: BCA
Website: www.ferronOther office(s) location(s):
phasrma.com
Share exported (%):
9001
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: s.burhan@galenium.com
Year established:
Ratu Hera Farida / Sufri Burhan

Galenium Pharmasia Laboratories
Jl. Aditya Warman No. 67 Kebayoran Baru
Jakarta, Indonesia
Tel: 6221-7228 601
Bank Ref:
Website:
Fax: 6221-6393 408

Legal status:

Share exported (%):
ISO 9001, GMP
USA, Singapore, Malaysia, Middle-East, Pakistan
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: NA
Ita / Hamzah
PT Guardian Pharmatama
Green Ville Maisonette FA - 18 - 19
Jakarta Barat, Indonesia
Tel: 6221-5656 253
Bank Ref: BCA
Website: www.gp.com
Headquarters location: NA
Fax: 6221-5656 638

Legal status:
Other office(s) location(s): Bekasi

9004
NA
NA
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: NA
Year established: NA
Susi
PT Hexpharmjaya
Gd. Sapta Mulia Lantai 3, Jl. Rawa Gelem V, Kav. OR No. 3B - Pulo gadung
jakarta Timur - Indonesia
Tel: 6221-4610 090
Fax: 6221-4613 882
Bank Ref: NA
Legal status: Limited
Other office(s) location(s): Jl. Pulo Lentut
No. 10 Pulo Gadung
Website: NA

NA
NA
NA
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
marketing@ikapharmindo.com
Year established:
Website:
www.ikapharmindo.com
Mrs. Winata / Mr. Martahan - Director

PT IKAPHARMINDO PUTRAMAS PHARMA
Jl. Pulogadung Raya No. 29, Kawasan Industri Pulogadung
Jakarta - Indonesia
Tel: 62-21-4682 6039
Fax: 62-21-4682 4501
Bank Ref: BCA
Legal status: PMDN


Share exported (%):

Austria, local
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
general@indofarmagroup.com
Ichsan Muchtar
PT Indofarma Tbk
Jl. Indofarma No. 1
Cikarang Barat - Indonesia
Website: www.indofarma.co.id
Tel: 6221-8832 971
Fax: 6621-8832 972/73
Bank Ref: Bank Mandiri
Legal status:
Other office(s) location(s): Manggarai,
Jakarta & in all province in Indonesia
Headquarters location: Cititung

Annual turnover (USD): 6.000.000up to 100
Share exported (%): 5
ISO 9001:2000
million
Asia, Africa, Europe, Afghanistan
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: interbat@interbat.co.id
Noto Sukamto - President Director

PT INTERBAT
Jl. Mampang Prapatan Raya No. 81
Jakarta Selatan 12790 - Indonesia
Tel: 62-21-7919 2000
Bank Ref:
Website: www.interbat.co.id
Fax: 62-21-7919 4000

Legal status: Local Comp
Share exported (%):

All Asia (imp / exp), Africa
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Michael Buyung Nugroho / As. Director

PT Kalbe Farma TBK
Gd. Enseval Jl. Letjen Suprapto Kav 4 C
Jakarta - Indonesia
Tel: 62-21-42873 8888
Bank Ref:
Website: www.kalbe.co.id
Fax: 62-21-4287 3678

Legal status:

Share exported (%):
9001/9001
Spanyol, Jepand, Korea (Import) / All Asia Tenggara, Africa (Export)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Sofiarman Tarmizi, Director

PT Kimia Farma tbk
Jl. Veteran No. 9
Jakarta Pusat - Indonesia
Tel: 3843907
Bank Ref: Duetche Banki
Website: www.dksh.com
Fax: 3454246 / 3454247

Legal status: PMA

Share exported (%):
9001
Germany, Thailand, Singapore, Switzerland, USA (Import)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
marketingpa@landson.co.id
Year established:
Jimmy Sudharta - Director

LANDSON - PT. PERTIWI AGUNG PHARMACEUTICAL INDUSTRI
Gd. Mensa II Lt.2, Jl. H.R Rasuna Siad Kav B-35, Kuningan
Jakarta - Indonesia
Website: www.landsond.co.id
Tel: 62-21-5209356-57 / 5271537
Fax: 62-21-5200509
Bank Ref:
Legal status:
Share exported (%):

Korea, Japan (Import) / Philippines, Malaysia
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Wiryawan - General Manager

PT Laniros Dian Pharma
Gedung Mugi Griya Lt. 4 Suite 406, Jl. MT Haryono Kav 10
Jakarta 12810 - Indonesia
Tel: 62-21-8308 464/65
Fax: 62-21-8379 2317
Bank Ref: BCA
Legal status:
Website:
Share exported (%):

Switzerland (Import)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Dr. Mustopo Widjaja (Director) / Drg Yuliani Dewi HRD
Company name:
PT LAPI Laboratories
Street POB:
Gedung Panjang Street 32
City Country:
Email: yuliani@lapi.co.id
Tel: 6902626
Fax: 6912955
Bank Ref: BCAi
Legal status: Local
Website:
www.lapilaboratories.com
Share exported (%):
9001
All Asia, India (Import), China
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Nomers Garciai
PT MediFarma
Jl. Rawa Gelam V Blok L Kav 11-13 Kawasan Industri PUlogadung
Tel: 4608808
Fax:
Bank Ref: BCA/Mandiri
Legal status: PMA
Website: www.medifarma

Share exported (%):
ISO 9001
USA, Germany, Austria
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
mkt@meiji.co.id/edyjoe@meiji.co.i
d
Website:
Edy Joe / Hadi Utomo - Director

PT MEIJI INDONESIA
JL. Tanah Abang II NO. 4
Jakarta Pusat 10160 - Indonesia
Tel: 62-21-3845584
Fax: 62-21-3457650 7 3483 4601
Bank Ref: BCA
Legal status:
Share exported (%):

Japan (import), Spain, Singapore, Vietnam, Africa (Export)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: contact@mbs.co.id
Dr. Budi Setya - Persident Director

PT Mensa Binasukses (Distributor)
Jl. Pulo Kambing 11 no. 26, Kawasan Industri Pulo Gadung
Jakarta - Indonesia 13260
Tel: 62-21-4601950
Fax: 62-21-4613577
Bank Ref:
Legal status:
Website: www.mbs.co.id
Share exported (%):

US, Germany, Asia (Import)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: merapi@merapi.net
Sindu - President Director / Bambang Giyanto

PT. MERAPI UTAMA PHARMA (Distributor)
Jl. Cilosari No. 25
Tel: 62-21-3141906, 3914870
Fax: 62-21-3905820, 3918329
Bank Ref: BCA
Legal status:
Website: www.merapi.net
Share exported (%):

ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: tan-wee-wha@merck.com
Website: www.msdindonesia.com
Tan Wee Hwa

PT Merck Sharp & Dohme Indonesia
Wisma BNI 46, Lt 27. Jl Jenderal Sudirman Kav 1
Jakarta, Indonesia
Tel: 62-21-5789 7000
Fax: 62-21-5789 7099
Bank Ref:
Legal status:
Share exported (%):

USA
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Eko Subagyo, Marketing Manager

Merck Indonesia
Plaza PP Lt. 4 Jl. TB. Simatupang No. 57
Jakarta - Indonesia
Tel: 62-21-841 3889
Bank Ref: Lippo Bank
Website: www.merck.com
Fax:
Legal status:
Share exported (%):

Germany (import) / South East Asia (export)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Monika / Marketing Manager

PT Natural Hilife
Jl. Kramat Kwitang l/11
Tel: 6221-3025 5610
Bank Ref:
Website:
Headquarters location: Magelang
Fax:
Legal status: Local
Share exported (%):

Japan (Import)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Hanadi.setiarto@novartis.com
Year established:
Hanadi Setiarto / Key Account Management

PT Novartis Indonesia
Wisma BNI 46 It. 35, Jl. Jendral Sudirman
Jakarta, Indonesia
Website: www.novartis.com
Tel: 6221-2513 251
Fax: 6221-2513 252
Bank Ref:
Legal status:

Share exported (%):
ISO 9000
Spain, Switzerland
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Junaedi / Marketing Manager

PT Novell Pharmaceutical Laboratories
Jl. Limo 40, Permata Hijau Senayan
Jakarta - Indonesia
Tel: 62-21-724 4110
Bank Ref: BCA
Website:
Fax: 62-21-724 4082


Share exported (%):
9001
Australia
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
organon.indonesia@organon.co.id
Year established:
Website: www.organon.co.id
Irawan - Director Finance Control

PT ORGANON
JL. Veteran - Bintaro Kebayoran Lama
Jakarta - Indonesia
Tel: 62-21-735 9988
Fax: 62-21-736 3736
Bank Ref: BCA/Niaga
Legal status: PMA

Share exported (%):

Belanda
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Danis S. Aman / Sales Director

PT Otsuka Indonesia
Perkantoran Hijau Arkadia Gedung A Lt. 4 Jl. TB. Simatupang Kav 88
Jakarta - Indonesia
Tel: 021 7827660
Fax: 021 782 7663/64
Bank Ref: BCA
Legal status:
Website: www.otsuka.co.id

Share exported (%):
9001, 14001
Korea (import), all Asia
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: jonathan@mensa.co.id
Year established:
Jimmy Sudhartai
PT Otto Pharmaceutical
Jl. HR Rasuna Said Kav B-34 Kuningan
Tel: 62-21-5254 108
Bank Ref:
Website:
Fax: 62-21-5256 309

Legal status:

Share exported (%):
9001
Korea, China
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Sutkno Sughondo, SH - General Manager

PT. PARIT PADANG
JL. Gunung Sahari XII No. 6-7
Tel: 62-21-6395 909
Bank Ref:
Website:
Fax: 62-21-6394 923

Legal status:
Share exported (%):

Local (Distributor)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Website: www.pfizerperduli.com
Lutfi Mardiansyah - Sales Director

PT Pfizer Indonesia
Wisma GKBI 10th Floor Suite 1005 Jl. Jend Surdirman No. 28
Tel: 5793 1088 / 89
Fax:
Bank Ref: BCAi
Legal status:

Share exported (%):
9001-2000
USA, AUS(I), AUS, ALL ASIA, KOREA, AFRICA
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Dr. Bina Suhendrai

PT Phapros Tbkl
Jl Simongan No. 131
Semarang 50148 - Indonesia
Tel: 61-24-607 330
Bank Ref:
Website:
Fax: 62-24-605 133

Legal status:
Share exported (%):

USA, Germany, Austria
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: andre@pharos.co.id
Andre Lembong
PT Pharos Indonesia
Jl. Limo 40 Permata Hijau 12220
Jakarta, Indonesia
Tel: 6221-7200 981
Bank Ref:
Website: www.pharos.co.id
Fax:
Legal status: Limited

Annual turnover (USD): 40.000.000
GMP
USA, Korea, Europa
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Dr. Hartoyo Sutandar - President Director

PT Pratapa Nirmala (Fahrenheit)
Jl. Raya Raden Saleh No. 4 Dinar Building Lt. 2
Jakarta - Indonesia
Tel: 62-21-3903 093
Fax: 62-21-9003 090
Bank Ref:
Legal status:
Website:
Share exported (%):

Korea, Jepang China (Import)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: sunardi@pyridam.com
Sunardi Sukowardi
PT Pyridam Farma Tbk
Jl. Kemandoran 8 No. 16
Jakarta - Indonesia
Tel: 6221-5307 551-52
Bank Ref: BCA
Website: www.pyridam.com
Fax: 6221-5329 049

Legal status: PMDN
Other office(s) location(s): Jl hanjawar,
Pacet Cianjur 43253

Annual turnover (USD): 10 juta U$
ISO 9001:2000, GMP
Hong Kong, Taiwan, Philippines, Malaysia, Cambodia
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Website:
www.sanofi.aventis.co.id
Evie Yulin / Marketing Director

PT Sanofi Aventis Group
Jl. Jenderal A. Yani Pulo Mas
Tel: 62-21-489 2208 / 489 5608
Bank Ref: Citibank
Fax: 62-21-7614 2717

Legal status:
Share exported (%):

France, South East Asia
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Bashir Ahmed - General Manager

SANOFI PASTEUR (Divisi of Aventis Pharma)
J. Jend A. Yani Pulo MAs
Tel: 62-21-4789 9763
Fax: 62-21-4786 2018
Bank Ref:
Legal status:
Website:
Share exported (%):

US, France (Import)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Website: www.scheringplough.com
Ferdinand A. Larosa
PT Schering Plough Indonesia TBK
Wisma Bank Dharmala Lt 10 Jl. Jenderal Sudirman Kav 28
Jakarta - Indonesia
Tel: 62-21-5225452
Fax: 62-21-5225446
Bank Ref:
Legal status:
Share exported (%):

USA
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Hindarto Lukas / Managing Director

Soho Industri Pharmasi PT
Jl. Pulogadung No. 6 Kawasan Industri Pulogadung
Tel: 6221-4605 550
Fax: 6221-4603 111
Bank Ref:
Legal status: PMDN
Website:

Share exported (%):
ISO 9001:2000
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: sunthi@indo.net.id
Website: www.sunthisepuri.com
Adiguna Sutowo, President Director

SUNTHI SEPURI PT
Wisma Nugra Santana Lt 5 Jl. Jenderal Sudirman Kav 7-8 Jak Sel 10220
Jakarta - Indonesia
Tel: 62-21-570 2500
Fax: 62-21-570 7151
Bank Ref:
Legal status:
Share exported (%):

Swiss (Import)
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email: NA
Lies Wahyuningrum
Takeda Pharmaceutical
J. Jend Sudirman
Jaskarta Selatan - Indonesia
Tel: 6221-5229 925
Bank Ref: NA
Website: NA
Headquarters location: Osaka
Fax: 6221-5229 926

Legal status: NA
Other office(s) location(s): Tambun
Bekasi

NA
NA
NA
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
InvestorRelation@theTempogroup
.net
Website:
Hartono Surya, National Sales Manager

PT Tempo Scan Pacific Tbk
Gedung Binamulia II Lt. 5, Jl. H.R Rasuna Said Kav 11
Jakarta - Indonesia
Tel: 62-21-520 1858
Fax: 62-21-520 1857
Bank Ref:
Legal status:
Share exported (%):

All Asia
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
rahmanta@pharmalink.com
Year established: NA
Paulun Rahmanta
PT Transfarma Medica Indah
Wisma Pondok Indah I, Unit 103, 1st Floor, Jl. Sultan Iskandar Muda Kav. V
Jakarta - Indonesia
Website: NA
Tel: 62-21-769 7323
Fax: 62-21-769 7528
Bank Ref: BCA
Legal status: NA
Other office(s) location(s): NA

NA
Italy, Germany
NA
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

ASIAHEALTHCARE 2008
Name and Title:
Company name:
Street POB:
City Country:
Email:
Year established:
Ms. Almitra I. Farid (Director)

PT TUNGGAL IDAMAN ABDI
Jl. A. Yani No. 7
Tel: 62-21-4890208
Bank Ref: BCA
Website:
Fax: 62-21-4891839
Legal status: PMDN
Share exported (%):

Germany
ACTIVITIES
Wholesaler/Retailer
Trader

Active
Pharma
Ingredients
(API)
ESSENTIAL DRUGS
1
Anaesthetics:
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Formulas/
Finished
Products
Local anaesthetics

NSAIMs
Opioid analgesics
Used to treat gout
DMARDs
Non-specific
Specific
Anthelminthics
Antibacterials
Antifungal
Antiviral
Antiprotozoal
For prophylaxis
Immunosuppressive
Cytotoxic medicines
Plasma substitutes
Antianginal
Antiarrhythmic
Antihypertensive
Antithrombotic
Lipid-lowering
Anti-inflammatory
Antifungal
Anti-infective
/antipruritic
Astringent
Ultraviolet
Diagnostic agents:
Ophthalmic
Radiocontrast media
Antiseptics
Disinfectants
Diuretics
17
18

Antiemetic
Laxatives
Used in diarrhoea
Estrogens
Anti-inflammatory
Androgens
Contraceptives
Ovulation inducers
Progestogens
Immunologicals:
20
Diagnostic agents
21
22
23
Oxytocics
24
Mydriatics
Local anaesthetics

panic attacks
27
Vaccines
26
19
25

tract
Oral
Parenteral
Miscellaneous

28
30
32
34
36
38
40
42
44
46
48
50
52
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
29
31
33
35
37
39
41
43
45
47
49
51
53
55
57
59
61
63
65
67
69
71
73
75
77
79
81
83
85

I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
EXCIPIENTS
86
88

cellulose)
87
89
I
I
E
E
90
91
92
93
94
95
96
98
97
Others (specify):

prophyl cellulose
paraben)

Joint sourcing
Joint distribution
Technology transfer
Other (specify):
OTHER INFORMATION

Indonesia: South-South Trade Promotion Programme

Diunggah oleh

Informasi Dokumen

Judul Asli

Hak Cipta

Format Tersedia

Bagikan dokumen Ini

Bagikan atau Tanam Dokumen

Opsi Berbagi

Apakah menurut Anda dokumen ini bermanfaat?

Apakah konten ini tidak pantas?

Hak Cipta:

Format Tersedia

Indonesia: South-South Trade Promotion Programme

Diunggah oleh

Hak Cipta:

Format Tersedia

SOUTH-SOUTH TRADE PROMOTION PROGRAMME

Supply and demand survey on pharmaceuticals and natural products Indonesia

Supply and demand survey on pharmaceuticals and natural products Indonesia

OBJECTIVES AND SCOPE OF THE REPORT .......................................................................................5

SUMMARY OF CONCLUSIONS AND RECOMMENDATIONS...................................10

Supply and demand survey on pharmaceuticals and natural products Indonesia

ASEAN Consultative Committee for Standards and Quality

Common Technical Dossier

Agreement on Common Technical Requirements

Asia Pacific Economic Cooperation

Association of Southeast Asian Nations

Accelerated Tariff Liberalization

Common Effective Preferential Tarriff

Cost, Insurance and Freight

Essential Drug List

Economic and Finance

Good Manufacturing Practices

International Trade Centre

Mutual Recognition Agreement

National Essential Drug List

Research and Development

Agreement on Trade-Related Aspects of Intellectual Property Rights

Value Added Tax

World Health Organization

World Trade Organization

Supply and demand survey on pharmaceuticals and natural products Indonesia

Objectives and scope of the report

Indicating possibilities for augmenting supplies and new investment opportunities

Determining technical assistance requirements in the areas of product development, packaging,

Supply and demand survey on pharmaceuticals and natural products Indonesia

Neuro Muscular System

Supply and demand survey on pharmaceuticals and natural products Indonesia

Vitamins & Minerals

Supply and demand survey on pharmaceuticals and natural products Indonesia

Anaestethics Local & General

Antidotes & Detoxifying Agents

Supply and demand survey on pharmaceuticals and natural products Indonesia

Supply and demand survey on pharmaceuticals and natural products Indonesia

SUMMARY OF CONCLUSIONS AND

Private healthcare facilities are expected to expand

Life expectancy average (years)

Sources: UN Common Database and various sources

Supply and demand survey on pharmaceuticals and natural products Indonesia

The pharmaceutical sector is tightly controlled by the government

Local pharmaceutical companies tend to be small-scale

Supply and demand survey on pharmaceuticals and natural products Indonesia

According to GP Farmasi (Indonesian Association of Pharmaceutical Companies), there are currently

Market size and characteristics

Excahnge rate: 1US$ equal Rp 9,200

Supply and demand survey on pharmaceuticals and natural products Indonesia

ECFIN is Economic and Finance Consultant

Supply and demand survey on pharmaceuticals and natural products Indonesia

Supply and demand survey on pharmaceuticals and natural products Indonesia

Geographical spread of pharmaceutical companies

GP Farmasi (Indonesian Association of Pharmaceutical Companies) members, to this point, only

Supply and demand survey on pharmaceuticals and natural products Indonesia

Source: Indonesian Association of Pharmaceutical Companies, 2007

The economic crises and production changes

Supply and demand survey on pharmaceuticals and natural products Indonesia

Installed production capacity

Type of medicines produced

Supply and demand survey on pharmaceuticals and natural products Indonesia

PT. Darya Varya Group